

1       **Development and Validation of a Paralimbic Related Subcortical Brain Dysmaturation**  
2       **MRI Score in Infants with Congenital Heart Disease**

3           William T. Reynolds, BS\*<sup>1</sup>, Jodie K. Votava-Smith, MD\*<sup>2</sup>, George Gabriel, PhD\*<sup>4</sup>,  
4           Vince Lee, BS<sup>5</sup>, Vidya Rajagopalan, PhD<sup>2</sup>, Yijen Wu, PhD<sup>4</sup>,  
5           XiaoQin Liu<sup>4</sup>, MD, Hisato Yagi, PhD<sup>4</sup>, Ruby Slabicki, BA<sup>5</sup>, Brian Gibbs, PhD,<sup>4</sup>  
6           Nhu N. Tran, PhD<sup>3</sup>, Molly Weisert, MD<sup>2</sup>, Laura Cabral PhD<sup>5</sup>,  
7           Subramanian Subramanian, M.D<sup>5</sup>, Julia Wallace, BA<sup>5</sup>, Sylvia del Castillo, MD<sup>6</sup>,  
8           Tracy Baust, BA<sup>7</sup>, Jacqueline Weinberg, MD<sup>8</sup>, Lauren Lorenzi Quigley, PhD<sup>10</sup>, Jenna Gaesser  
9           MD<sup>9</sup>, Sharon H. O’Neil PhD<sup>11</sup>, Vanessa Schmithorst PhD<sup>5</sup>, Rafael Ceschin, PhD\*\*<sup>5</sup>  
10          Cecilia Lo, PhD\*\*<sup>4</sup>, and Ashok Panigrahy, MD\*\*<sup>5</sup>

- 11  
12  
13       1. Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA  
14       2. Department of Pediatrics, Division of Cardiology, Children’s Hospital Los Angeles, and Keck School of  
15       Medicine, University of Southern California, Los Angeles, CA  
16       3. Fetal and Neonatal Institute, Division of Neonatology Children’s Hospital Los Angeles, Department of  
17       Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA  
18       4. Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA  
19       5. Department of Pediatric Radiology, Children’s Hospital of Pittsburgh of UPMC and University of Pittsburgh  
20       School of Medicine, Pittsburgh, PA  
21       6. Department of Anesthesiology, Critical Care Medicine Children’s Hospital Los Angeles, Los Angeles, CA  
22       7. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA  
23       8. Department of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA  
24       9. Department of Neurology and Child Development, University of Pittsburgh School of Medicine, Pittsburgh,  
25       PA  
26       10. Cardiac Neurodevelopmental Care Program, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA  
27       11. Division of Neurology and The Saban Research Institute, Children’s Hospital Los Angeles, Department of  
28       Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA  
29

30       \*co-first authors; \*\*co-senior authors

31  
32  
33       Short Title: Subcortical paralimbic abnormalities and outcomes in infant and CHD mouse model  
34  
35

36       **Address Correspondence and Reprint Request to:**

37       Ashok Panigrahy, MD  
38       Department of Pediatric Radiology  
39       Children’s Hospital of Pittsburgh of UPMC  
40       4401 Penn Avenue  
41       Pittsburgh, PA 15224  
42       Tel: 412-692-5510  
43       Fax: 412-864-8622  
44       [apanigrahyranjan@gmail.com](mailto:apanigrahyranjan@gmail.com)  
45

46 **Abstract**

47 **Background**

48 Brain magnetic resonance imaging (MRI) of infants with congenital heart disease (CHD) shows brain immaturity  
49 assessed via a cortical-based semi-quantitative score. Our primary aim was to develop an infant paralimbic-related  
50 subcortical-based semi-quantitative dysmaturation score, a brain dysplasia score (BDS), to detect abnormalities in  
51 CHD infants and predict clinical outcomes. Our secondary aim was to validate our BDS in a preclinical mouse  
52 model of hypoplastic left heart syndrome.

53 **Methods**

54 A paralimbic-related subcortical BDS, derived from structural MRIs of infants with CHD, was correlated with  
55 clinical risk factors, regional cerebral volumes, feeding and 18-month neurodevelopmental outcomes. The BDS  
56 was validated in a known CHD mouse model named *Ohia* with two disease-causing genes, *Sap130* and *Pchda9*. To  
57 relate clinical findings, RNA-Seq was completed on *Ohia* animals.

58 **Findings**

59 BDS showed high incidence of paralimbic-related subcortical abnormalities (including olfactory, cerebellar, and  
60 hippocampal abnormalities) in CHD infants (n=215) compared to healthy controls (n=92). BDS correlated with  
61 reduced cortical maturation, developmental delay, poor language and feeding outcomes, and increased length of  
62 stay. *Ohia* animals (n=63) showed similar BDS findings, and RNA-Seq analysis showed altered  
63 neurodevelopmental and feeding pathways. *Sap130* mutants correlated with a more severe BDS whereas *Pcdha9*  
64 correlated with a milder phenotype.

65 **Interpretation**

66 Our BDS is sensitive to dysmaturational differences between CHD and healthy controls, and predictive of poor  
67 outcomes. A similar spectrum of paralimbic-related subcortical abnormalities exists between human and *Ohia*  
68 mutants suggesting a common genetic mechanistic etiology.

69 **Funding**

70 National Library of Medicine, Department of Defense, National Heart, Lung, and Blood Institute, National Institute  
71 on Aging, Southern California Clinical and Translational Sciences Institute, Additional Ventures Foundation,  
72 Saban Research Institute, Children's Hospital Los Angeles Clinical Services Research Grant, and National Institute  
73 of Nursing Research. Funding award numbers can be found in the acknowledgment section.

74 **Non-standard Abbreviations and Acronyms**

75 ECM: Episcopic Confocal Microscopy, CHD: congenital heart disease, HLHS: hypoplastic left heart syndrome,  
76 MRI: magnetic resonance imaging, WMI: white matter injury, GA: gestational age, PCA: post-conceptional age,  
77 BDS: brain dysplasia score.

78 **Keywords**

79 Olfactory Bulb, Hippocampus, Cerebellum, Feeding Outcome, Neurodevelopmental Outcome, *Ohia* HLHS Mouse  
80 Mutants

81

82 **Research In Context**

83 **Evidence before**

84 The number of clinical and research MRI studies in neonatal/infant CHD subjects has increased dramatically in the  
85 last two decades. Previous studies have developed brain MRI scores that have focused on cortical structural  
86 maturation and acquired brain injury. Paralimbic-related subcortical regions are important for the development of  
87 cognitive and visumotor functions in early development. Levering a large infant brain MRI dataset and a large-  
88 scale genetic mouse screen, we theorized that a paralimbic-related subcortical brain MRI score could assist  
89 clinicians with outcome prediction in CHD infants.

90 **Added Value**

91 This work aims to develop a subcortical morphological scoring system that could be applied to either clinical or  
92 research MRI scans and could improve the ability of clinicians and neuroradiologists to predict not only those at  
93 risk for suboptimal neurodevelopmental outcomes but also associated co-morbidities. We discovered not only are  
94 there paralimbic-related subcortical structural abnormalities that a brain MRI score can detect but also that this  
95 score predicted poor language outcomes, poor feeding outcomes, and increased post-surgical length of stay. We  
96 also found that the genetic model of hypoplastic left heart syndrome, the most severe form of CHD, also  
97 demonstrated a similar pattern of paralimbic related subcortical brain abnormalities.

98 **Implications**

99 This novel scoring system developed by our group has implications for early detection of at-risk CHD individuals  
100 for poor outcomes, both neurodevelopmental and quality of life. This subcortical paralimbic brain dysplasia score  
101 is a simple tool that can be easily added to neuroradiological workflows that can lead to better outcome prediction  
102 for children with CHD. Our scoring system helps us to better serve our population, allowing clinicians and  
103 researchers to prognosticate highest risk individuals who will benefit from the earliest forms of intervention.

104

## 105 Introduction

106 Congenital heart disease (CHD) affects 1% of live births each year.<sup>1,2</sup> As the surgical care for CHD  
107 improves, there remains lingering increased risk of poor neurodevelopmental outcomes for patients with CHD  
108 across the lifespan. The mechanism for neurodevelopmental disabilities in non-syndromic CHD is unknown and is  
109 thought to be related to fetal exposure to reduced substrate delivery/hypoxia or a genetic underpinning. Genetic  
110 abnormalities are detected in approximately 50% of children with syndromic CHD, and in approximately 10% of  
111 children without a recognizable clinical phenotype.<sup>3</sup> Significant overlap is present between deleterious de novo  
112 mutations and previously reported mutations associated with neurodevelopmental disorders,<sup>4</sup> suggesting that  
113 genetic mutations that cause CHD, may also be important in the etiology of neurodevelopmental deficits.<sup>5,6</sup> Smaller  
114 brain volumes and dysmature brain structures are seen in neonates and fetuses with CHD before cardiac surgery,  
115 suggesting that innate and/or prenatal factors may play an important role in altering brain development.<sup>7-9</sup> Within  
116 our current understanding of neurogenesis, there is little known about the role that deep grey and subcortical  
117 regions play in mediating poor neurodevelopmental outcomes in relation to genetic alterations. Recent animal  
118 models and correlative neuropathological studies suggest that cortical dysmaturation is linked to white matter  
119 abnormalities, including developmental vulnerability of the subplate in CHD.<sup>10,11</sup> Recent neuroimaging studies  
120 have documented paralimbic related subcortical morphological abnormalities in CHD patients across the  
121 lifespan,<sup>12-16</sup> but the relationship between paralimbic-related subcortical morphological abnormalities and clinical  
122 and neurodevelopmental outcomes in CHD is also unknown.<sup>17-20</sup>

123 Children with CHD are at a higher risk of developing brain dysmaturation, a generalized term  
124 encompassing abnormal and delayed development of brain macro- and microstructure<sup>21-25</sup>. CHD patients are also at  
125 risk for acquired brain injury, including infarcts and small vessel disease across lifespan as detected by  
126 conventional neuroimaging studies. Clinical neuroimaging studies are also becoming more common to obtain in  
127 patients during the peri-operative period based on recently published guidelines. Most conventional semi-  
128 quantitative MRI scoring systems in CHD patients have exclusively focused on either acquired brain injury or  
129 cortical maturation assessment, particularly in the neonatal period.<sup>26-33</sup> We recently developed and validated an  
130 infant semi-quantitative score that extending beyond cortical maturation and acquired brain injury to include  
131 morphological alterations in paralimbic-related subcortical structures (including cerebellum, hippocampus,  
132 olfactory bulb abnormalities), CSF-related abnormalities (including increased extra-axial CSF in frontotemporal  
133 regions) and the corpus callosum known as a brain dysplasia score (BDS), informed by preclinical models of  
134 CHD, specifically hypoplastic left heart syndrome (HLHS). We focused our analysis on paralimbic-related  
135 subcortical structures that are known to undergo neurogenesis in early development and across the lifespan,  
136 including the olfactory bulbs, hippocampus, and cerebellum. We have recently described a similar pattern of  
137 structural subcortical dysmaturation both in human infants with CHD and genetically relevant ciliary motion  
138 dysfunction, and also in relation to preclinical models of CHD including hypoplastic left heart syndrome  
139 (HLHS).<sup>34-40</sup> We have previously shown that the BDS correlates with abnormal neonatal brain white matter  
140 connectivity patterns<sup>41</sup> but have yet to validate this scoring system in a large dataset in relation to clinical and  
141 neurodevelopmental outcomes. Here, we used quantitative structural brain magnetic resonance imaging (MRI) in  
142 infants with CHD to test the hypothesis that subcortical morphological measurements could be assessed using a  
143 qualitative scoring system termed brain dysplasia score (BDS) and that these subcortical structures are potential  
144 predictors of not only infant cortical maturation and regional brain volumes but also are predictors of poor clinical  
145 and neurodevelopmental outcomes.<sup>12-15,21,42,43</sup>

146 To further validate our subcortical BDS from a genetic perspective, we leveraged the *Ohia* mouse model  
147 of HLHS recovered from a large-scale mouse mutagenesis screen. In *Ohia* mice with HLHS, phenotypic mutations  
148 primarily arise from homozygous mutations in two genes, a chromatin modifying protein Sin3A-associated protein  
149 130 (*Sap130*), and protocadherin A9 (*Pcdha9*), a cell adhesion protein in the a-protocadherin gene cluster.<sup>44</sup>  
150 Importantly, both genes are known to have important roles in brain health-related outcomes. For example, the  
151 clustered protocadherins provide cell surface diversity by encoding unique neuronal identity essential for patterning  
152 synaptic connectivity.<sup>45</sup> Mice with PCDHA mutations have deficiencies in both brain connectivity and  
153 neurobehavioral deficits.<sup>46</sup> Moreover, mutations in both PCDHA and SIN3A are associated with autism and Rett  
154 Syndrome in humans.<sup>47-49</sup> Importantly, the SIN3A complex also contains transcription factors known to regulate  
155 developmental and lifespan neurogenesis.<sup>50,51</sup> Given the prominent roles of PCDHA and SIN3A in human  
156 neurogenesis and brain development, we used the *Ohia* mouse model for further validation of the hypothesis that  
157 the subcortical BDS could be used as a proxy of subcortical morphological and connectivity quantitative  
158 measurements and predict clinical and neurodevelopmental outcomes in human CHD infants.

## 159 **Methods**

### 160 **Ethics**

161 The study was HIPAA compliant and approved by the institutional review board (IRB) of Children’s Hospital Los  
162 Angeles (CHLA) and Children’s Hospital of Pittsburgh (CHP) of the University of Pittsburgh Medical Center  
163 (UPMC) and written informed consent was obtained from each subject, except for a few patients in which MRI was  
164 obtained clinically, and retrospective use of the data was approved by the IRB protocol (CHLA-CCI-09-00055,  
165 CCI-10-00235, University of Pittsburgh- 20030213,19100215, 19030204). All experiments were performed per the  
166 institutional guidelines and regulations.

### 167 **Patient Recruitment and Clinical Data Collection**

168 This study is a secondary analysis of neonates with CHD (term and preterm) undergoing brain MRI scans who  
169 were recruited as part of a prospective, observational study from two large medical centers, CHLA and CHP.  
170 Neonatal CHD cases were prospectively recruited from (1) pregnancies with fetal CHD confirmed with fetal  
171 echocardiography and (2) postnatal admissions to the cardiothoracic intensive care unit postoperatively between  
172 2002-2016 and (3) infants with both preterm and term CHD undergoing clinically indicated brain MRI scans at  
173 approximately term-equivalent gestational age (GA) were recruited both prospectively and retrospectively in the  
174 peri-operative period from 2002-2017. The inclusion criterion was critical CHD defined as a heart defect expected  
175 to require corrective or palliative cardiac surgery during infancy. Exclusion criteria for the CHD included  
176 documented major chromosomal abnormalities and major congenital brain malformations. Normal referents were  
177 recruited (1) from healthy pregnant volunteers and (2) postnatally from a normal newborn nursery. An additional  
178 comparison group was included which was comprised of preterm infants without CHD who were recruited from a  
179 high-risk NICU at the same institutions as previously published.<sup>20,52-54</sup> Details about the recruitment strategies have  
180 been described in multiple previous publications.<sup>12,34,35,55-63</sup>

181 There were 423 subjects that met the inclusion criteria for this study: 307 full term neonates (215 with CHD and 92  
182 term controls) and 116 preterm neonates (65 with CHD born 25-36 weeks GA, and 51 preterm control patients born  
183 24 – 36 weeks GA) (Figure 1). This is the dataset for which we performed the primary analysis of calculating a  
184 BDS and comparing the difference between groups.

185

### 186 **Research Scans**

187 Brain MRIs for CHD infants were obtained in either the preoperative (usually between 1-7 days) or postoperative  
188 period (up to 13 weeks postnatally, but often sooner). The age range for healthy controls ranged between birth and  
189 thirteen weeks postnatally, encompassing the same range of the CHD infants. Preoperative research brain imaging  
190 was conducted when on CHD subjects when the cardiothoracic intensive care unit (CTICU) team/cardiology team  
191 determined the patient was stable for transport to the MRI scanner. Postoperative research scan was performed at  
192 less than three months of postnatal age either as an inpatient or outpatient. Most of our scans were research  
193 indicated and as such no additional sedation/anesthesia was given for the scan purpose. Most of the pre-operative  
194 scans were performed on non-intubated non-sedated patients; however, if the patient was intubated and sedated for  
195 clinical reasons at the time of the scan, their clinically indicated sedation continued under care of the primary  
196 CTICU. team. The post-operative scans were performed when the infant was clinically stable and thus were done  
197 as “feed and bundle” scans without sedation. To minimize movement during imaging, infants were secured in Med-  
198 Vac Immobilization Bag (CFI Medical) with multiple levels of ear protection, including ear plugs, MiniMuffs  
199 (Natus Medical Incorporated), and standard headphones.

### 200 **Clinical Scans**

201 Patients in the clinically indicated brain MRI group were scanned at approximately term-equivalent GA either in  
202 the pre- or post-operative period as previously published.<sup>58</sup> The post-operative scan for both preterm CHD and term  
203 CHD groups was performed at least within 52 weeks corrected postconceptional age.

### 204 **Neonatal Brain MRI Protocol**

205 MRI studies were acquired: (1) GE 1.5T (Signa LX, GE Healthcare, Milwaukee, WI) MR system using a custom-  
206 built neonatal transmit-receive head coil, (2) Philips 3T Achieva MR System (Ver. 3.2.1.1) using standard 8-



207 channel SENSE head coil; and (3) Siemens Skyra 3T scanner using a 20-channel coil. Conventional imaging  
208 studies were acquired with the MRS studies and included a 3D coronal SPGR sequence (TE= 6 ms; TR=25 ms,  
209 FOV=18 cm; matrix=256 × 160; slice thickness 1.5 mm, spacing 0 mm) or axial and sagittal T1-weighted FLAIR  
210 sequences (TE=7.4, TR=2100; TI=750; FOV=20 cm; Matrix=256 × 160), axial T2-weighted FSE sequence  
211 (TE=85ms, TR=5000ms, FOV=20 cm, matrix =320 × 160 or 256 × 128) and a diffusion-weighted sequence  
212 (TE=80; TR=10000; FOV=22 cm; Matrix = 128 × 128; slice thickness =4.5 mm, spacing 0 mm). The 3D T1-  
213 weighted, T2-weighted, and diffusion-weighted images were reviewed by two pediatric neuroradiologists for  
214 evidence of punctate white matter lesion, hypoxic-ischemic injury, acute focal infarction, and hemorrhage as  
215 previously described and were used to construct dichotomized and composite brain injury scores.<sup>64</sup>

## 216 **Subcortical brain dysplasia MRI score (BDS) derivation**

217 Our development of the subcortical based BDS has been derived from observations from both preclinical mouse  
218 CHD mutants and human CHD infants from recent studies from our group.<sup>21,22,36,39,65-67</sup> The evaluation for brain  
219 dysplasia in our human CHD population is conducted by examining the following structures: cerebellar  
220 hemispheres (both left and right together), cerebellar vermis, right olfactory bulb, right olfactory sulcus, left  
221 olfactory bulb, left olfactory sulcus, hippocampus, choroid plexus, brain stem, corpus callosum, and supratentorial  
222 extra-axial fluid. Supplemental Figure 1 depicts a visualization of how the BDS was calculated. Except for the  
223 supratentorial extra-axial fluid, each of the structures listed were evaluated on whether they appear normal or  
224 abnormal. For cerebellar hemispheres and cerebellar vermis, they were scored for hypoplasia (small volume) and  
225 dysplasia (abnormal shape). Likewise, the olfactory bulbs and sulci were evaluated as separate structures for  
226 purposes of scoring. Based on the finding, a binary number score is given for each structure, with a score of 0  
227 assigned for normal and a score of 1 for abnormal. For olfactory bulbs and sulci, both hypoplastic and absent  
228 findings are treated as abnormal and given a score of 1. For supratentorial extra-axial fluid, the structural features  
229 demonstrate different gradations of abnormality – none, mild, moderate, or severe fluid accumulation – and thus  
230 successively higher integer scores are assigned as the severity of abnormality becomes greater. The integer scores  
231 for each of the structures were then summed to create the BDS with “olfactory correction” which treats both absent  
232 and hypoplastic olfactory abnormalities as one score point, thus making the weighting of the olfactory system in  
233 line with cerebellum and hippocampus. Higher BDS values can be thought of as having a “worse” score as subjects  
234 had more abnormalities present. A subset of cases was reviewed by two raters to validate the scoring.

235 Similar to our BDS, a brain injury score was calculated for each human subject. The composite brain injury score  
236 consisted of four criteria with each criterion being scored as a 1 if present in the subject. The four criteria were  
237 hemorrhage, infarct, hypoxic ischemic injury, and periventricular white matter injury (PWMI). A dichotomized  
238 version was also calculated for each individual and was scored as a 1 or 0. If the original brain injury score was  
239 greater than 0, then the composite score was a 1; otherwise, the score was a 0. A visual depiction of the brain injury  
240 scores can be found in Supplemental Figure 2.

241

## 242 **Structural Co-variate Analysis: Cortical Maturation Score and Regional Brain Volumetric Analysis**

243 We correlated BDS with a classic cortical Total Maturation Score (TMS) and regional brain volumes. A cortical  
244 TMS was calculated for all subjects with brain MRI included in this analysis. A subset of the full cohort (term  
245 controls and CHD scanned at 3T imaging, n=105) underwent cerebral regional volumetric segmentation for  
246 structural co-variate analysis. To determine the relationship between our qualitative BDS and quantitative regional  
247 morphological dysmaturation, we performed regional brain morphometric techniques including volumetric  
248 segmentation of total intracranial cerebral spinal fluid (CSF), cortical grey matter, cortical white matter, deep grey  
249 nuclei, brainstem, and cerebellum using a neonatal and infant brain segmentation age-specific atlas. We further  
250 segmented total intracranial CSF into three compartments: supratentorial extra-axial CSF, infratentorial extra-axial  
251 CSF and intraventricular CSF. Our group used the above age-specific atlas to build a semi-automated brain  
252 parcellation pipeline for use in neonates and young infants (Supplemental Figure 3). The automated processing  
253 pipeline which was previously described in by our group,<sup>35</sup> was developed using Nipype and interfaces with several  
254 image registration algorithms using age-appropriate neonatal/infant templates to accommodate different post-  
255 conceptional ages in the patient cohort. Our methodology for volumetric segmentation of neonatal brain has been  
256 previously described.<sup>68,69</sup> We further refined this methodology for the current study because of the wide range of  
257 post-conceptional ages of neuroimaging studies and the resulting need to use a range of neonatal and infant age-  
258 appropriate templates. We also performed validation experiments to ensure optimal performance with this

259 neonatal/infant CHD cohort with mild brain dysplasia. We processed each patient's T1 and T2 volumetric images in  
260 parallel to optimize registration parameters uniquely to each tissue contrast. First, the images were cropped, and  
261 brain extracted using FSL BET. The volumetric images (T1 and T2 separately) were then biasfield corrected using  
262 FSL's FAST segmentation. We then registered the bias-field corrected images to the tissue contrast specific and  
263 post-conceptual age matched template, created by Serag et. al,<sup>70</sup> using a non-linear registration from Advanced  
264 Normalization Tools (ANTs). The output transformations were inversed and applied to the template space tissue  
265 probability maps provided with the neonatal atlas. This transformation results in subject-space tissue probability  
266 maps. We calculated tissue volumes by thresholding the partial volume maps at a visually acceptable lower bound  
267 and extracting the volume from the binarized mask. The subject-space segmentations were manually checked for  
268 accuracy by an expert pediatric neuroradiologist (AP) blinded to patient diagnosis.

269

### 270 **Clinical Risk Factor Analysis**

271 We correlated BDS with clinical risk factors. Analysis of clinical risk factors included a subset of subjects with  
272 critical CHD who required corrective or palliative cardiac surgery within the first month of life who were  
273 prospectively enrolled for pre and postoperative brain MRI scans from 2009-2016. Two hundred ninety-one  
274 subjects were prospectively enrolled from June 2009 to October 2016. Of these subjects, 158 met exclusion criteria  
275 including 57 with no MRI done, 38 due to prematurity, 38 passed the age threshold, 11 expired preoperatively, 10  
276 had no neonatal surgery and 4 had a postnatal major genetic diagnosis. Of the 133 term CHD infants with brain  
277 MRI meeting inclusion criteria, 90 subjects had sufficient imaging quality for structural analysis and clinical risk  
278 factor data collected. comprised the study group for this analysis. Subjects that had a known major chromosomal  
279 abnormality, were premature ( $\leq 36$  weeks of age), died prior to MRI or did not require neonatal cardiac surgery  
280 were excluded in this analysis. Clinical data was collected from the electronic medical records and included 18  
281 patient-specific and 9 preoperative variables associated with preoperative scan and 6 intra-operative (e.g.,  
282 cardiopulmonary bypass, deep hypothermic circulatory arrest times) and 12 postoperative variables associated with  
283 postoperative scan, as described previously.<sup>59,71</sup> CHD lesions were classified in several ways (not mutually  
284 exclusive) including postnatal cyanosis, presence of aortic arch obstruction, single vs. double ventricles, d-  
285 transposition of the great arteries, conotruncal defects, heterotaxy, whether the lesion alters fetal cerebral substrate  
286 delivery and severity of this alteration (normal, altered, severely altered).

### 287 **Feeding Outcomes**

288 We correlated the BDS with feeding outcomes. The feeding outcome study group consisted of term infants with  
289 CHD who had neonatal brain MRI with brain dysplasia score between 2003-2015, enrolled both prospectively for  
290 research MRI and retrospectively after clinical MRI, at CHLA and CHP. Subjects with major gastrointestinal  
291 anomalies or surgeries, a diagnosis of CHARGE syndrome, death within the first 30 days of life, or death prior to  
292 initiation of feeds were excluded from the feeding analysis. For the feeding study, we evaluated 177 term infants  
293 with CHD who had MRI that were used to calculate BDS as described above. Of those, 32 were excluded  
294 including 14 with major gastrointestinal anomalies or surgeries, 1 with brain anomaly, 6 with CHARGE syndrome,  
295 and 11 that died in the first 30 days or prior to initiation of feeds. Therefore, the feeding analysis group consisted of  
296 145 subjects of which 81 were from CHLA and 64 from CHP. The inpatient medical records were assessed for the  
297 following feeding-related variables: presence of dysphagia, aspiration, gastroesophageal reflux, gastrointestinal  
298 dysmotility, intestinal malrotation, vocal cord paralysis, use of enteral tube feeding (including nasogastric,  
299 nasojejun, or surgically placed gastric or jejunal tubes), lack of oral feeding prior to neonatal hospital discharge,  
300 and length of neonatal hospitalization.

### 301 **Neurodevelopmental Outcomes**

302 For neurodevelopmental outcomes assessment, Bayley Scales of Infant and Toddler Development or Battelle  
303 Developmental Inventory were completed by a licensed psychologist in a subset of patients. A total of 90 subjects  
304 (CHLA n=32, CHP n=58) had early neurodevelopmental outcome data obtained between 15 to 18 months postnatal  
305 age. The standard score for each developmental domain (motor, language/communication, cognitive, and  
306 social/emotional) was evaluated. Developmental delay was defined as a standard score greater than 2 standard  
307 deviations below the mean in 1 developmental domain. Global developmental delay was defined as a standard  
308 score greater than 2 standard deviations below the mean in 2 or more developmental domains. The following  
309 criteria was used: Average= Standard Score 90 to 109 (25<sup>th</sup> to 74<sup>th</sup> percentile); Low Average= Standard Score 80 to

310 89 (9<sup>th</sup> to 24<sup>th</sup> percentile); Below Average= (2<sup>nd</sup> to 8<sup>th</sup> percentile); Exceptionally low= (<2<sup>nd</sup> percentile). The data  
311 was then dichotomized to yes/no for (1) developmental delay, (2) global developmental delay, and (3) below  
312 average for each subject to facilitate harmonization between the two different test exams across both sites.

### 313 **Mouse Screen Analysis**

314 A retrospective analysis was carried out on the mouse lines described by Li et al.<sup>72</sup> In brief, a forward recessive  
315 mouse screen was carried out using N-ethyl-N-Nitrosourea in which 3700 mouse lines, defined by G1 sire, were  
316 screened for defects. Defect screening was completed through ultrasound scanning, micro-computed tomography  
317 (CT), micro-magnetic resonance imaging (MRI) and visual inspection of G3 offspring. Resulting mutant cardiac  
318 phenotypes were confirmed through necropsy, or histopathologic analysis. Further analysis was completed  
319 examining the craniofacial and gross brain abnormalities discovered within the screen. Lines in which a mutant was  
320 recovered in the original screen were analyzed for both craniofacial and gross brain abnormality. Consistent  
321 phenotype in at least three mice was required for a line to be considered abnormal with a craniofacial or brain  
322 abnormality. An additional mouse model which recapitulates the phenotype of Joubert syndrome was analyzed  
323 prior to any analysis on the main *Ohia* line to validate method and findings. The mouse model was previously  
324 validated by Damerla et al.<sup>73</sup> This Joubert syndrome mouse mode is colloquially called Heart Under Glass (*Hug*)  
325 and contains a S235P missense mutation in *Jbts17*. The *Hug* mice recapitulate the brain phenotype of Joubert  
326 syndrome presenting with decreased number of cerebellar fissures.

### 327 **Episcopic Confocal Microscopy (ECM)**

328 Head samples were removed following necropsy and fixed in 4% PFA solution for a minimum of 72 hours. After  
329 fixation, samples were prepared for ECM via three graded ethanol baths of 10%, 20%, and 40% overnight at room  
330 temperature. Samples were then transferred to a Sakura Tissue Tek VIP 5 Tissue Processor where they were  
331 dehydrated using increasing percentages of warmed ethanol baths and eventually perfused with paraffin wax.  
332 Samples were embedded in paraffin blocks to be sectioned coronally. 3D reconstructed images stacks were used for  
333 brain scoring and volumetric analysis. A diagram for the ECM workflow can be found in Supplemental Figure 4.

### 334 **Mouse Brain Dysplasia Scoring**

335 A group of three reviewers reviewed 84 cases consisting of 69 *Ohia*, five CRISPR/CAS9, and 10 wild type  
336 samples. Reviewers came to a consensus for each structure scored. In total seven structures were included the  
337 mouse brain scoring including hippocampus, cerebellum, cerebrum, left and right olfactory bulbs, brain stem, and  
338 midbrain. Hippocampus, cerebellum, and both olfactory bulbs were scored for aplasia, hypoplasia, and dysplasia.  
339 Cerebrum, brain stem and midbrain were scored for hypoplasia and dysplasia only. Each instance of abnormality  
340 received a binary score of zero or one. Brain Dysplasia Score (BDS) was a sum of each area of the brain. Two  
341 other BDS metrics were calculated, one being a binary scoring of any cerebellar or hippocampal abnormalities and  
342 the another being a binary score if any abnormality was present in the sample at all. Cerebellar folds were counted  
343 using a sagittal view in the middle slice of the brain.

### 344 **Mouse Brain Segmentation**

345 Tiff images were converted to NIFTI images using ITK-Snap and FSL. Images were down sampled 4x using  
346 FMIRB's Linear Registration Tool (FLIRT). Resulting images were manually segmented into 16 discreet structures  
347 using ITK-Snap. Structures segmented included right hippocampus, right olfactory bulb, right subcortical area,  
348 right cortex, intracranial space, midbrain, left hippocampus, left olfactory bulb, left subcortical area, left cortex,  
349 extra-axial space, cerebellum, pons, medulla, hypothalamus, and choroid plexus. Due to the required processing  
350 methods for ECM, CSF is removed from the brain and replaced with paraffin wax. The space voided of CSF has  
351 been labeled as intracranial space and extra-axial space. Structures above the tentorium were combined to form a  
352 supratentorial volume and an infratentorial volume was also calculated. Infratentorial volumes consisted of the  
353 pons, medulla, and cerebellum, while the supratentorial volumes were composed of the hippocampus,  
354 hypothalamus, olfactory bulbs, subcortical areas, cortex, and midbrain.

### 355 **Genotype Analysis**

356 We explored the relationship of *Sap130/Pcdha9* genotype and brain morphology in the mouse modeling. When  
357 comparing the risk stemming from the BDS for animals from the *Ohia* line, different genotypes were grouped into  
358 6 distinct groups. Group A: *Sap130(m/m)* and *Pcdha9(m/m)*, Group B: *Sap130(m/m)* and *Pcdha9(m/+)*, Group C:



359 *Sap130*(m/m) and *Pcdha9*(+/+), Group D: *Sap130*(m/+) and *Pcdha9*(m/m), Group E: *Sap130*(+/+) and  
360 *Pcdha9*(m/m), and lastly, Group F: *Sap130*(m/+) or (+/+) and *Pcdha9*(m/+) or (+/+).

### 361 **Mouse Genotype Groupings and Comparisons**

362 For greater power in subsequent analysis, mice with similar genotypes were pooled into Groups. Group ABC  
363 consisted of mice which were homozygous mutant for *Sap130* (m/m), irrespective of their *Pcdha9* genotype. An  
364 additional Group, AB, contained mice which were homozygous mutant for *Sap130* (m/m), and either homozygous  
365 mutant or heterozygous for *Pcdha9* (m/\*). To study the effect of homozygous mutations in the *Sap130* gene,  
366 Group ABC was compared against wildtype animals. Group ABC was then compared against Group F. Group F  
367 can only be heterozygous for *Sap130* and *Pcdha9*, so any effect of the homozygous mutant *Sap130* alleles would  
368 be removed in this group. This pairing should show effects of the homozygous *Sap130* mutation more concretely.  
369 To assess if any of the effect is coming from the *Pcdha9* genotype, Group AB was then compared to F. Group AB  
370 differs from Group ABC by removing samples that contained, wildtype *Pcdha9* genotyped animals. If *Pcdha9* is  
371 partially, or in large part, responsible for the observed phenotype, removing wildtype *Pcdha9* samples from the  
372 ABC Group should increase incidence and effects should become more significant. To further isolate the effect of  
373 *Sap130*, Group A was compared against Group C with the difference between groups being homozygous mutant  
374 *Pcdha9* (Group A) vs wildtype (Group C). Lastly, Group B was compared against Group D. Group B is  
375 homozygous *Sap130* and heterozygous *Pcdha9*, and Group D is the opposite, *Sap130* heterozygous, and *Pcdha9*  
376 homozygous mutant. If either homozygous gene is more significant than the other, the effect could be seen within  
377 this comparison.

378

### 379 **RNaseq Analysis**

380 RNA was isolated from brain tissue samples of 4 *Ohia* mutant animals and 5 littermate controls at embryonic day  
381 E13.5-E14.5, libraries were constructed and sequenced on the Illumina HiSeq 2000 platform (BGI Americas), and  
382 differential gene expression analysis was conducted as previously described (Gabriel et al. Biorexiv paper). The online  
383 Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used to perform gene ontology (GO)  
384 functional enrichment analysis.

385

### 386 **Statistical Analyses for Human Studies**

387 **Primary analysis:** SAS statistical software was used to carry out human statistical analysis. Our primary analysis  
388 compared the derived BDS between neonates with CHD and controls. This analysis was performed using  
389 multivariate regression and three major co-variates were included in the model: gender, postconceptional age  
390 (PCA=gestational age plus postnatal age), time of MRI scan timing of scan relative to cardiac surgery (pre- vs post-  
391 operative). Multi-variate regression with false discovery rate (FDR) correction was used, to correct for multiple  
392 comparisons. The FDR is one way of conceptualizing the rate of type 1 errors in null hypothesis testing when  
393 conducting multiple comparisons. Whether BDS is association with sex difference, GA, or PCA was assessed in  
394 the entire study cohort.

395 **Secondary analysis:** Secondary analysis was repeated within the CHD only group, with birthweight and the  
396 presence of genetic abnormality included as additional comparisons with BDS. Furthermore, whether pre- or post-  
397 operative and pre-term or term status correlated with BDS was also analyzed within the CHD group. As an  
398 additional secondary analysis, within the CHD group, BDS was compared to the presence of various injuries and  
399 cortical maturation features. Additional secondary analyses including correlation of BDS with feeding data and  
400 neurodevelopmental outcome which consisted of linear and logistic regression with false discovery rate (FDR)  
401 correction for multiple comparisons; FDR-adjusted p-value <0.05 was considered significant.

### 402 **Statistical Analyses for Mouse Studies**

403 Volumetric analysis of mouse individual structures was carried out using SAS statistical software. Both raw and  
404 normalized by total brain volume values were compared in any models generated. We completed an ad hoc  
405 analysis to delineate the relationship between BDS and regional brain volumes, clinical risk factor and heart lesion  
406 subtypes on our primary outcome measures. Clinical variables were compared using a three-way ANCOVA  
407 (analysis of covariance) between wild-type, *Ohia*, and *Hug* animals. We then compared each of the groups  
408 mentioned above to each other using pairwise T-tests.

409 **Role of Funders**

410 Funding sources were not involved in patient recruitment, data collection, analysis, or formation of the manuscript.  
411 All work was original and completed by the authors without interaction by the funding sources.

## 412 **Results**

### 413 **Comparison of Brain Injury/Cortical Maturation Score (TMS) between CHD and Control Cohorts:**

414 The preterm CHD and term CHD cohort demonstrated increased incidence of brain injury compared to their  
415 gestational-aged, matched controls. Specifically, the CHD preterm cohort demonstrated increased incidence of  
416 focal infarcts ( $p = 0.0295$ ) and punctate white matter lesions ( $p = 0.0231$ ) compared to the preterm control cohort.  
417 The term CHD cohort demonstrated increased rates of hemorrhage ( $p = 0.0284$ ), focal infarct ( $p = 0.0035$ ),  
418 punctate white matter lesions ( $p < 0.001$ ), dichotomized injury composite score ( $p < 0.001$ ), and injury composite  
419 score ( $p < 0.001$ ) compared to the term control cohort (Supplemental Table 1).

420 When comparing the categories of the cortical maturation score (TMS), the term CHD cohort had widespread  
421 reduced cortical maturation (in all cortical lobes except occipital) compared to term control cohort, while the  
422 preterm CHD only differed from preterm controls in the myelination category (Supplemental Table 2).

### 423 **Derivation of Human BDS in Human Infant CHD:**

424 There was a high incidence of olfactory, hippocampal, and cerebellar abnormalities in the preterm and term CHD  
425 cohorts compared to both preterm and term control cohorts respectively (Table 1). Within the univariate analyses,  
426 there was no significant correlation between BDS and sex, GA, or PCA within the entire study cohort (Table 2A).  
427 Within the CHD cohort, there was no correlation between BDS and pre/postoperative status, preterm/term status, or  
428 birth weight. Higher BDS in the CHD cohort was correlated with known genetic abnormalities (Table 2B), which  
429 remained a significant association in the multivariable analysis (Table 2C). BDS was highly correlated with cortical  
430 immaturity by cortical maturation scores including frontal cortex ( $p < 0.0001$ ), insular cortex ( $p < 0.0001$ ), and  
431 cortical folding ( $p = 0.0016$ ), even after controlling for PCA at the scan (Table 3). There was no significant  
432 correlation between BDS and any categories of brain injury (Table 3). Within a subset of cases the inter-rater  
433 reliability was calculated and resulted in reviewers one and two receiving high scores for most metrics included in  
434 the BDS calculation. Notable exceptions were for cortical folding ( $\kappa = 0.18, 0.00$ ), myelination ( $\kappa = 0.35,$   
435  $0.02$ ), supratentorial extra-axial fluid ( $\kappa = 0.35, 0.05$ ), and germinal matrix ( $\kappa = 0.48, 0.00$ ). Other values  
436 for Cohen's kappa measure for the BDS can be found in Supplemental Table 3.

### 437 **Human Infant BDS and Regional Cerebral Volumes:**

438 Higher BDS correlated with smaller left and total cerebellar volume, smaller deep grey matter and brain stem  
439 volumes, and increased infra-ventricular and supra-tentorial CSF volumes in the entire sample (term CHD and term  
440 control cohorts combined) (Table 4). Increased BDS was more strongly correlated with reduced cerebellar volume,  
441 reduced cortical volumes, and increased CSF volume in the term CHD cohort compared to the term control cohort  
442 (Table 4).

### 443 **Human Infant BDS and Clinical Risk Factors:**

444 When assessed against clinical risk factors in term CHD infants, the BDS did not correlate with birth factors,  
445 anthropomorphic data, cardiac lesion type, or intraoperative factors. (Supplemental Table 4A-D). The BDS did  
446 correlate with age of under 7 days at surgery ( $p < 0.048$ , Supplemental Table 4B), increased length of hospitalization  
447 ( $p < 0.0447$ , Supplemental Table 4D), and need for G-tube placement during the neonatal hospital stay ( $p < 0.01$ ,  
448 Supplemental Table 4D). Of note, we found no correlation between BDS and MRI field strength/scanner type  
449 (Supplemental Table 5).

### 450 **Human Infant BDS and Feeding Outcomes:**

451 Lack of oral feeding before neonatal hospital discharge was associated with multiple morphological abnormalities  
452 of the components of the BDS including cerebellar hemispheres and vermis, hippocampus, bilateral olfactory bulbs  
453 and olfactory sulci, corpus callosum, increased supratentorial extra-axial fluid, as well as total increased BDS.  
454 Hospital length of stay was associated with dysplasia of the cerebellar hemispheres and vermis, hippocampus,  
455 choroid plexus, brainstem, increased supratentorial axial fluid, and BDS. A diagnosis of dysphasia was associated  
456 with dysplasia of the brain stem ( $p = 0.001$ ). Gastrointestinal dysmotility, aspiration, gastroesophageal reflux,  
457 malrotation, and vocal cord paralysis demonstrated no significant associations with brain dysplasia. Figure 2 panels  
458 A-D show some of the variations in hippocampal anatomy seen in the human population compared against that  
459 seen in the mouse in panels E and F. Figure 3 demonstrates olfactory bulb abnormalities in human infant CHD vs

460 control (A/C) and the mouse model (B/D) . Figure 4 demonstrates cerebellar abnormalities in the human infant  
461 CHD vs controls (A-top) and the mouse model (A-bottom).

#### 462 **Human Infant BDS and Neurodevelopmental Outcomes:**

463 Increased BDS correlated with developmental delay in at least one domain including motor, cognitive,  
464 language/communication, or social/emotional ( $p < 0.02$ ), and specifically with poor expressive language  
465 development ( $p < 0.016$ ) in a subset of the original sample tested at 15-18 months of age ( $n=90$ ), given in Table 6.

#### 466 **Mouse CHD Screen Results**

467 From the original mouse screen for CHD, 3208 mouse pedigrees were screened, and 390 (12.16%) mutant lines  
468 were discovered. Of the 390 mutant lines, 214/390 (54.87%) had some form of craniofacial anomaly and 69/390  
469 (17.69%) lines had a severe brain anomaly. Within those categories, craniofacial and brain anomalies, 174/214  
470 (81.31%) and 62/69 (89.86%) had co-occurrence of CHD, respectively. Supplemental Figure 5 demonstrates some  
471 of the craniofacial abnormalities seen during the screening. 68 lines contained features of both types of anomalies,  
472 and of those 68 lines, 61 also exhibited CHD. A summary of the results can be seen in Figure 5

#### 473 **Hug Model Mouse ECM Validation**

474 To validate the ECM method, a mouse model, colloquially called Heart Under Glass or Hug, for Joubert syndrome  
475 with a S235P missense mutation in *Jbts17* was analyzed prior to analysis of Ohia mice. Joubert syndrome is a  
476 ciliopathy associated with cerebellar abnormalities and other birth defects. In addition, Hug mice also had higher  
477 incidences of BDS ( $p = 0.0161$ ), and specifically, in the cerebellum-hippocampus dichotomized BDS ( $p = 0.0154$ ).  
478 Compared to wildtype mice, Hug mice showed an overall increase in cerebellar abnormalities ( $p < 0.001$ ) and a  
479 decrease in the number of cerebellar fissures ( $p = 0.0023$ ).

#### 480 **Ohia Mouse Model Brain Dysplasia Scoring**

481 ECM analysis was completed on 69 Ohia mutant neonatal mice. There was an increase in the BDS in the Ohia  
482 group compared to the wildtype group ( $p < 0.001$ ) (Table 7). With regards to individual subcortical abnormalities  
483 (which make up the composition of the BDS), the cerebellum showed the highest incidence of abnormality with  
484 dysplasia being present in 49/67 (73.13%) of animals scored and was highly significant compared to control  
485 animals ( $p < 0.001$ ). Ohia mutants also showed a decrease in the number of cerebellar fissures ( $p < 0.001$ )  
486 compared to the wild type group. The Ohia mutants also showed an increase in incidence of hippocampal dysplasia  
487 ( $p = 0.002$ ), cerebral dysplasia ( $p = 0.003$ ), left olfactory bulb aplasia ( $p = 0.024$ ), left olfactory bulb any  
488 abnormality ( $p = 0.006$ ), right olfactory bulb aplasia ( $p = 0.02$ ), and right olfactory bulb any abnormality ( $p =$   
489  $0.007$ ) (Table 7). Supplemental Figure 6 demonstrates some of the common phenotypes seen in Ohia mice.  
490 Findings of aplasia, hypoplasia or dysplasia were common in the olfactory bulb, cerebellum, and/or hippocampus.  
491 Additionally holoprosencephaly was a coincidental finding in Ohia mice with 42/69 (60.9%) showing some signs  
492 of holoprosencephaly. Supplemental Figure 7 shows Ohia animals and two examples of the holoprosencephaly  
493 observed in this population.

#### 494 **Ohia Brain Dysplasia Scoring within CHD Subgroupings**

495 To examine the relationship between CHD lesions and brain dysmaturation, the co-occurrence of different brain  
496 anomalies and any form of CHD was compared. We compared within the Ohia cohort looking at BDS and  
497 cerebellar fissures and found that the presence of CHD increased the BDS and reduced cerebellar fissures ( $p <$   
498  $0.001$ ) (Table 8). Looking at other forms of cardiac sub-lesions, there was no significant differences between BDS  
499 and cerebellar folds (Table 8).

500 In Ohia animals there were 10 brain structures which showed an increased incidence of abnormalities in animals  
501 with CHD. Those structures included hippocampal dysplasia ( $p = 0.043$ ), cerebral hypoplasia ( $p = 0.008$ ), cerebral  
502 dysplasia ( $p < 0.001$ ), cerebellar dysplasia ( $p < 0.001$ ), left olfactory bulb aplasia ( $p < 0.001$ ), left olfactory bulb  
503 any abnormality ( $p < 0.001$ ), right olfactory bulb aplasia ( $p < 0.001$ ), right olfactory bulb any abnormality ( $p <$   
504  $0.001$ ), brainstem dysplasia ( $p = 0.016$ ), and midbrain dysplasia ( $p = 0.0062$ ) (Supplemental Table 6A). Comparing  
505 single versus biventricular morphology, defects were more common in the cerebellum in double ventricular mice ( $p$   
506  $< 0.001$ ) (Supplemental Table 6A). When comparing conotruncal vs non-conotruncal defects, mice with  
507 conotruncal defects showed an increased in the occurrence of hypoplasia in the cerebrum ( $p = 0.037$ )  
508 (Supplemental Table 6B) Within cyanotic vs acyanotic cardiac defects, mice with acyanotic defects showed

509 increases in the incidence of left olfactory bulb hypoplasia ( $p = 0.018$ ) and any defect in the cerebellum ( $p = 0.037$ ).  
510 Lastly, looking at mice with and without arch obstructions, mice with arch obstruction showed an increase in the  
511 occurrence of any defect in the cerebellum ( $p = 0.048$ ) (Supplemental Table 6B).

### 512 **Ohia Mouse Model Regional Brain Volumes**

513 Ohia mutants demonstrated a significant decrease in raw (non-normalized) volumes of the right subcortical ( $p =$   
514  $0.044$ ), left subcortical ( $p = 0.041$ ), cerebellar ( $p = 0.005$ ) and supratentorial volume ( $p = 0.037$ ) volumes (non-  
515 normalized) compared to wild type control. Ohia mutants also demonstrated an increase in the intraventricular  
516 volume ( $p = 0.009$ ) compared to wild type controls (Supplemental Table 7).

517 Normalizing volumes to total brain volume showed Ohia animals also exhibited a significant increase in medullary  
518 ( $p = 0.024$ ) and intraventricular normalized volume (normalized to total brain volumes). ( $p = 0.015$ ). Ohia animals  
519 also demonstrated a decrease in normalized supratentorial volumes ( $p = 0.01$ ) compared to wild type controls  
520 (Supplemental Table 7).

### 521 **Ohia Mouse Model Regional Brain Volumes within CHD Subgroupings**

522 There were no differences in raw (non-normalized) volumes between Ohia mice with and without CHD. Looking at  
523 single versus biventricular morphology, mice with biventricular heart defects showed increases in the volumes of  
524 the right subcortical areas ( $p = 0.006$ ), left subcortical area ( $p = 0.036$ ), and the pons ( $p = 0.024$ ) (Supplemental  
525 Table 8a). Comparing conotruncal against non-conotruncal heart defects, mice with conotruncal defects showed an  
526 increased in the right subcortical area ( $p = 0.043$ ) (Supplemental Table 8b). Mice with acyanotic defects  
527 demonstrated an increase in the volume of the left hippocampus ( $p = 0.044$ ) (Supplemental Table 8b). There were  
528 no differences in volume noticed between mice with and without arch obstructions.

529 After normalizing raw volumes to total brain volume different regions showed significance between groups.  
530 Between CHD and non-CHD Ohia mice, Ohia mice with CHD showed increased volumes in the right cortex ( $p =$   
531  $0.026$ ), midbrain ( $p = 0.044$ ) and cerebellum ( $p = 0.044$ ). Comparing normalized volumes within single and  
532 biventricular groupings found that single ventricular morphology heart defect mice had increased choroid plexus  
533 volumes ( $p < 0.001$ ). (Supplemental Table 9a). There were no significant findings looking between groups of  
534 conotruncal vs non-conotruncal, cyanotic vs acyanotic, or arch obstruction vs no arch obstruction (Supplemental  
535 Table 9b).

### 536 **Ohia Mouse Model Brain Dysplasia Scoring within Genotype Subgroupings**

537 Comparing genotypes within the Ohia cohort, samples were first grouped based on genotypes. The two groups with  
538 the most samples were group A which consisted of Sap130 and Pcdha9 double mutants and group F consisted of  
539 animals which did not have a Sap130 or Pcdha9 homozygous mutant genotype (Table 9). Both groups showed high  
540 incidence rates of olfactory bulb, cerebellar, hippocampal, and brainstem abnormalities (Table 9). Using Group  
541 ABC mentioned in the Mouse Genotype Groupings section in the methods, values of hippocampus and cerebellar  
542 BDS ( $p < 0.001$ ) and BDS total (all structures) were greater ( $p < 0.001$ ) in Group ABC compared to wildtype  
543 (Table 10).

544 Within the different genotype groups there were various findings. Groups A and B had 19/24 (79.17%) and 6/8  
545 (75%) of mice exhibiting some form of holoprosencephaly. Additionally, those groups had the high rates of CHD  
546 and the various subtypes of CHD (i.e., conotruncal, single ventricular morphology, cyanotic defects, and arch  
547 obstructions) (Supplemental Table 10).

548 When comparing ABC vs WT, to determine homozygous Sap130 mutation difference compared to controls, 10  
549 structures studied showed greater incidence values in ABC compared to wildtype. Those structures included  
550 dysplastic hippocampus ( $p < 0.001$ ), hypoplastic cerebrum ( $p = 0.40$ ), dysplastic cerebrum ( $p < 0.001$ ), dysplastic  
551 cerebellum ( $p < 0.001$ ), aplastic left olfactory bulb ( $p = 0.001$ ), combination of left olfactory bulb ( $p < 0.001$ ),  
552 aplastic right olfactory bulb ( $p = 0.001$ ), combination of right olfactory bulb ( $p < 0.001$ ), dysplastic brainstem ( $p =$   
553  $0.037$ ), and the dichotomized BDS ( $p < 0.001$ ) (Supplemental Table 7a).

554 Comparing groups ABC vs. F to determine homozygous Sap130 mutation difference compared to no homozygous  
555 mutation in either gene (at most hetero or WT for either mutation), hippocampal and cerebellar BDS was different  
556 between groups with ABC, a higher incidence ( $p = 0.008$ ) (Table 10). Eight structures had significantly increased  
557 incidence in group ABC compared to F. Structures included hypoplastic cerebrum ( $p = 0.021$ ), dysplastic cerebrum



558 (p = 0.016), dysplastic cerebellum (p < 0.001), aplastic left olfactory bulb (p = 0.035), combination of left olfactory  
559 bulb (p = 0.010), aplastic right olfactory bulb (p = 0.022), combination of right olfactory bulb (p = 0.018), and  
560 dichotomized BDS (p = 0.021). Additionally, the ABC group had an increased value for the hippocampus and  
561 cerebellum BDS (p = 0.008) (Supplemental Table 7a).

562 In comparing groups AB vs. F, (homozygous Sap 130 mutation and homo/heteroPCDHA9 vs no hippocampal and  
563 cerebellar BDS was significantly different between groups (p 0.021) (Table 10). Seven structures showed  
564 significant differences in the rate of abnormalities; structures included hypoplastic cerebrum (p = 0.035), dysplastic  
565 cerebrum (p = 0.019), dysplastic cerebellum (p = 0.001), aplastic left olfactory bulb (p-value = 0.039), combination  
566 of left olfactory bulb (p = 0.023), aplastic right olfactory bulb (p = 0.023), and combination of right olfactory bulb  
567 (p = 0.023) (Supplemental Table 7b). Comparing groups A vs C, only 2 structures were found significant. Those  
568 structures were dysplastic brainstem (p = 0.028) and dysplastic midbrain. (p = 0.042) (Supplemental Table 7b).  
569 Comparing groups B vs D, only aplastic hippocampus (p 0.029) and any defect in hippocampus (p = 0.014) were  
570 found to be significant (Supplemental Table 7c).

### 571 **Ohia Mouse Model Regional Brain Volumes within Genotype Subgroupings**

572 Looking at volumes for brain regions between genotype groups, in group ABC vs wild type, six areas were found  
573 to be significantly different with mice in group ABC having reduced volumes including the right subcortical area (p  
574 = 0.006), right cortex (p = 0.047), left subcortical area (p = 0.007), cerebellum (p-value = 0.003), supratentorial  
575 volume (p = 0.013), and total brain volume (p = 0.028) (Supplemental Table 11a).

576 In group ABC vs F, mice in group ABC showed significant volume reductions in eight structures. Structures  
577 included right hippocampus (p-value = 0.041), right subcortical areas (p = 0.050), right cortex (p = 0.016), left  
578 hippocampus (p-value = 0.031), left olfactory bulb (p = 0.048), left cortex (p = 0.022), supratentorial volume (p-  
579 value = 0.018), and total brain volume (p = 0.022) (Supplemental Table 11a). Similarly comparing groups AB vs.  
580 F, mice in group AB showed significant reductions in volumes in eight structures. Differences occurred between  
581 right hippocampus (p = 0.021), right subcortical areas (p-value = 0.023), right cortex (p = 0.029), left hippocampus  
582 (p-value = 0.024), left subcortical areas (p = 0.038), left cortex (p = 0.029), supratentorial volume (p = 0.014) and  
583 total brain volume (p = 0.014) (Supplemental Table 11b). Lastly, comparing group A vs C, animals in group A  
584 showed significant reductions in four areas including the right subcortical area (p = 0.022), left subcortical area (p  
585 = 0.034), infratentorial volume (p = 0.047), total brain volume (p = 0.049) (Supplemental Table 11b).

586 After normalizing raw volumes to total brain volume, multiple brain regions showed significant differences  
587 between groupings. The ABC group demonstrated increased volume of the midbrain (p = 0.027) and medulla (p =  
588 0.005) and decreased volume of the right olfactory bulb (p = 0.037) and supratentorial region (p = 0.009) compared  
589 to the wild type groups (Supplemental Table 12a). The ABC group demonstrated significant increases in volume in  
590 three areas including the cerebellum (p = 0.010), medulla (p = 0.043), and choroid plexus (p = 0.012) compared to  
591 the F group. Additionally, the right cortex volume was reduced in animals in group ABC compared to F (p = 0.028)  
592 (Supplemental Table 12a).

593 Comparing groups AB vs F, mice in group AB demonstrated three structures with significant increases in volume  
594 including the cerebellum (p = 0.012), pons (p = 0.049), and choroid plexus (p = 0.029). There were no significant  
595 differences between groups A vs C and B vs D (Supplemental Table 12b).

### 596 **Mouse CHD/Ohia RNA-seq**

597 RNA-seq transcriptome profiling in term Ohia brains showed changes in genes involved in learning and memory,  
598 feeding behaviors, neuronal differentiation, and synaptic transport (Figure 6) Sap130 chromatin  
599 immunoprecipitation sequencing (CHIP-seq) looking at targets associated with Sap130 in brain tissue revealed a  
600 total of 644 genes being associated with cardiac and brain associated genes. Of those 644 genes, 106 and 324 were  
601 cardiac and brain genes, respectively, with the remaining 214 genes being associated with both brain and cardiac.  
602 The top three phenotypes associated with the Sap130 CHIP-seq analysis were global brain delay, abnormal brain  
603 development, and abnormal nervous system development.

### 604 **Crisper/CAS Phenotype Validation**

605 Crisper/CAS9 mice were also processed via ECM for validation of phenotype associated with Ohia mice. Three  
606 different crisper/CAS mice were developed to validate, a Sap130/Pcdha9 double mutant, Sap130 only and Pcdha9  
607 only. Brain scoring was performed like Ohia mice and findings support a similar phenotype. In the Sap130/Pcdha9

608 double mutant mice analyzed, they were found to exhibit a severe phenotype characterized by smoothed  
609 cerebellum, aplastic or highly dysplastic olfactory bulbs, and aplastic hippocampus. Other animals showed a  
610 pattern of holoprosencephaly. The Sap130 crisper animal showed a severe phenotype as well with smooth  
611 cerebellum, absent or extremely abnormal olfactory bulbs, and either holoprosencephaly or an abnormal  
612 hippocampus. In the Pcdha9 crisper animal, the phenotype was milder and presented with a cerebellum that while  
613 dysplastic did present with fissures unlike the double mutant or Sap130 crisper animal, a semi-normal appearing  
614 olfactory bulb and hippocampus. The phenotype was more severe in animals having mutations in the Sap130 gene.  
615 A visual representation of the defects found in Crisper/CAS9 mice can be found in Supplemental Figure 8. A  
616 similar pattern of severe olfactory bulb and hippocampal structural abnormalities was seen in our human  
617 population. Supplemental Figure 9 shows the Crisper/CAS animals compared to a human subject with severe brain  
618 dysmaturation.  
619

## 620 Discussion

621 Our study validates a paralimbic related subcortical based semi-quantitative BDS, which has proven to be  
622 sensitive to dysmaturational differences between CHD and control infants as well as sensitive to  
623 neurodevelopmental outcomes within CHD infants, including associations with early language, clinical and feeding  
624 outcomes. Most conventional semi-quantitative MRI scoring systems in CHD patients have exclusively focused on  
625 either acquired brain injury or cortical maturation assessment, particularly in the neonatal period.<sup>26-33</sup> In this study,  
626 we demonstrated that not only is it possible to generate a paralimbic-related subcortically informed scoring system,  
627 but that such a scoring system holds important information regarding outcomes for CHD infants at risk for atypical  
628 neurodevelopment. The key subcortical components of our scoring system included subcortical structures that are  
629 known to be part of para-limbic neural networks including the olfactory bulb, the hippocampus, the cerebellum and  
630 the deep grey structures like the striatum. Furthermore, we showed that there is a distinct similarity between  
631 findings seen in CHD infants when compared to a preclinical mouse model of CHD suggesting similar mechanisms  
632 of brain dysmaturational.

633 In our study, we found a high incidence of paralimbic related subcortical abnormalities including  
634 olfactory, cerebellar, hippocampal, and brainstem abnormalities in infants with CHD compared to controls. We  
635 found similar olfactory bulb defects in the preclinical mouse model that we also see in our human CHD population.  
636 These abnormalities were used to derive a semi-quantitative subcortical abnormality or brain dysplasia score  
637 (BDS). We found that this BDS correlated with reduced cortical maturation (measured with the classic TMS),  
638 increased CSF volume and increased deep grey volume (striatum/thalamus). In contrast, the BDS did not correlate  
639 with GA, preterm status, cardiac lesion subtype, birth factors, intraoperative factors, or different vendor MRI/field  
640 strength. BDS did correlate with developmental delay and poor expressive language development. The BDS also  
641 correlates with age at surgery, increased length of hospitalization and need for G-tube placement. A more detailed  
642 evaluation of factors surrounding feeding and individual brain dysplasia parameters found correlations between  
643 lack oral feeding prior to neonatal hospital discharge and dysplasia of multiple brain areas as well as the BDS, and  
644 additionally with hospital length of stay which is likely the sequela of feeding dysfunction. Interestingly,  
645 swallowing dysfunction was associated with dysplasia of the brain stem.

646 An important component of our paralimbic-related subcortical BDS scoring system is the hippocampus.  
647 We found a consistent pattern of dysmaturational in the hippocampus, including severe forms of hippocampal aplasia  
648 or dysplasia in both mice and human subjects. Research has indicated that reductions in hippocampal volume and  
649 functional correlates in adolescents and adults resulted in an increased rate of neurodevelopmental impairment<sup>74,75</sup>.  
650 Fontes et. al found that hippocampal shape and volumetric abnormalities found within CHD subjects can be  
651 predictive of impaired executive function. It is possible that the hippocampus is particularly vulnerable to early  
652 injury in CHD individuals as it is a brain region particularly susceptible to injury related to hypoxemia or  
653 hemodynamic instability. Latal et al found that reductions in hippocampal volume correlated with reductions in  
654 total IQ, working memory, and verbal comprehension. Lastly, one study looking at maternal stress found that  
655 reductions in hippocampal volumes are present in utero, consistent with previous volumetric findings of CHD<sup>76</sup>.  
656 Wu et. al concluded that universal screening looking at maternal stress is important, as early identification of  
657 hippocampal abnormalities is imperative.

658 Another important component of our paralimbic-related subcortical scoring system was the cerebellum.  
659 Cerebellar dysfunction has been linked with adverse neurodevelopmental outcomes<sup>77-79</sup>. Stoodley found that  
660 cerebellar damage or malformation present in early stages of development to be more detrimental than when  
661 obtained in adulthood, and theorized that injuries could affect cerebral-cerebellar circuits that are crucial to  
662 development and learning.<sup>78</sup> Zwicker et. al found that preterm infants with exposure to morphine in the neonatal  
663 period had decreased cerebellar volumes and worse neurodevelopmental outcomes.<sup>79</sup> Additionally, our group has  
664 previously shown that CHD children with reduced cerebellar volumes scored worse in tests for working memory,  
665 inhibitory control, and mental flexibility<sup>80</sup>. We also demonstrated that the superior surface of the cerebellum,  
666 primarily composed of the posterior lobe and the midline vermis, is an area particularly susceptible to alterations in  
667 morphology, indicating possible regions specifically affected by dysmaturational in CHD.<sup>35</sup> Previous literature in  
668 combination with our BDS findings show the importance of the cerebellum toward neurodevelopment and suggest  
669 that insults or injury affecting proper cerebellar development may impact neurodevelopmental outcomes. Figure 4  
670 demonstrates some of the commonalities seen between the mouse and human cerebellum; of note are the abnormal  
671 number cerebellar fissure and small size.

672 An important subcortical structure that was noted to be abnormal in the human BDS score volumetric  
673 correlation analysis and in the preclinical modeling was the striatum. In infancy, striatal connectivity is related to  
674 later motor and affective outcomes<sup>81-83</sup>, with previous research suggesting there are abnormalities in CHD<sup>84</sup>,  
675 potentially linking disrupted development with future behavior. The striatum forms a neural network with indirect  
676 and direct connectivity with other subcortical paralimbic components of the BDS score including the cerebellum,  
677 hippocampus and olfactory bulb. As such the developing striatum is part of a dense, interconnected network that  
678 supports motor function, reward processing, and cognition<sup>85,86</sup>, with circuitry specialized for affective based  
679 learning and olfactory reward. Supported by work in animal models and adults, the olfactory bulb directly projects  
680 to the olfactory tubercle<sup>87</sup>, a part of the ventral striatum, specialized for olfaction and containing significant  
681 dopamine neurons<sup>88,89</sup>. Together with innervations to the striatum from the hippocampus and amygdala<sup>90-93</sup>, the  
682 ventral striatum has been suggested to represent odor valence cues and instigate goal-directed behavior<sup>87</sup>, facilitated  
683 by additional input from piriform cortex and prefrontal cortex<sup>94-96</sup>. Output from the ventral striatum proceeds to the  
684 pallidum and then the thalamus, which then closes the feedback loop with prefrontal cortex<sup>97,98</sup>. An important  
685 structure in this loop is the orbitofrontal cortex, which plays an important role in maintaining changing odor  
686 representations but also more broadly in decision making and stimulus evaluation<sup>99</sup>. Integrated into these loops are  
687 other subcortical structures, including the cerebellum, which also has a significant role in movement and more  
688 recently emphasized role in cognition and language<sup>100</sup>. Through the thalamus and pons, the cerebellum indirectly  
689 projects to putamen, pallidum and the subthalamic nucleus<sup>101,102</sup>. These outputs may be topographically organized,  
690 converging on both the ventral striatum and frontal areas, with suggested involvement in appetitive reward<sup>103</sup> and  
691 strategic motor learning<sup>104</sup>. Disruption of this interconnected network is likely captured by BDS scores, which are  
692 then sensitive to striatally relevant neurodevelopmental outcomes.

693 Within the *Ohia* mouse model the two main driver genes were *Sap130* and *Pcdha9*, and while both genes  
694 were necessarily to have cardiac phenotype, both genes were not required to have neuroanatomic abnormalities.  
695 Additionally, *Sap130* mutations presented with a more severe brain phenotype compared to *Pcdha9* mutations.  
696 This is interesting as knock-out mice for *Sap130* are embryonically lethal whereas *Pcdha9* knock-out mice are  
697 viable suggesting that *Sap130* may have a more upstream effect whereas *Pcdha9* is more downstream.<sup>105</sup> *Sap130*  
698 functions as a subunit of the histone deacetylase dependent co-repressor complex which has roles transcriptional  
699 regulation and has been specifically mentioned to be required for recovery from hypoxia.<sup>106</sup> *Pcdha9* is a member of  
700 the protocadherin alpha gene cluster which are important plasma membrane proteins for cell-cell connections,  
701 neural projects, and synapse formation.<sup>107</sup> Interestingly both genes show overlap in connectomes with chromatin  
702 and histone modification pathways.<sup>44</sup> Alterations in histone modifying pathways have been linked to various forms  
703 of CHD.<sup>108-110</sup> It's likely that there are many other genes and gene pairings that could cause a similar  
704 neurodevelopmental phenotype as it's possible the main driver could be epigenetic dysregulation resulting in  
705 altered differential expression of genes required for signaling and migration. Incorrect timing for migrating neural  
706 cells might explain why preterm babies and CHD babies look phenotypically similar in regard to  
707 neurodevelopment. Looking at the genetics of the preclinical mouse model could not be conclusive as to the  
708 etiology of the human CHD neurodevelopmental issues; however, we demonstrate spectra of cardiac and brain  
709 anatomical abnormalities associated with the different genetic combinations of the *Ohia* mouse, parallel to those  
710 seen in human subjects.

711 CHD subjects have a documented risk of poor neurodevelopmental outcomes although the specific  
712 mechanism is unknown.<sup>111-115</sup> Additionally, neurodevelopmental impairments can continue to affect individuals  
713 well past infancy and into adolescence and early adulthood.<sup>116-121</sup> There are two main hypotheses with regard to the  
714 origin of injury to the brain and subsequent neurodevelopmental deficits that arise from the injury; intrinsic patient  
715 factors including genetics or altered substrate delivery due to the cardiac malformation. There have been studies  
716 looking at the heritability of CHD to determine the genetic causes which resulted in the finding that CHD most  
717 likely has a genetic component. CHD is particularly common in genetic syndromes caused by aneuploidy defects;  
718 ranging anywhere from 20% - 100% of individuals with trisomies 13, 18, and 21 as well as and monosomy X<sup>122</sup>,  
719 though these syndromic cases account for a relatively low amount of the total CHD population. Additionally, rates  
720 of CHD are increased when there are abnormal chromosomal structural syndromes such as deletions, insertions,  
721 and copy number variants.<sup>123</sup> Known de novo single nucleotide polymorphisms account for approximately 10% of  
722 CHD cases, roughly the same amount that can be attributed to environmental factors.<sup>123,124</sup> However, the vast  
723 majority of CHD individuals have an unknown origin of the cardiac defect as well as subsequent  
724 neurodevelopmental abnormalities. To overcome this missing data, work has begun looking at previously  
725 uncharacterized de novo mutations in mice, singling out genes with human homologs and which have high

726 expression in the heart. When looking at only the homologous genes, researchers found that between CHD and  
727 control individuals, there was no significant difference between rates of generic de novo mutations; however, when  
728 comparing genes with high cardiac expression, CHD subjects had much higher rates of mutations in protein-  
729 altering mutations.<sup>125</sup> This recent work into the genetic origins of CHD has shown that even when the cause of the  
730 insult is unknown, the cause of CHD is likely genetic possibly through the alteration of genes which affect similar  
731 downstream pathways.

732 Whether the genetic insult is the main driver or whether the mutations leave the individual susceptible to  
733 other forms of injury is unknown. Our group has previously looked at how the developing subcortical paralimbic-  
734 related structures of the brain can be linked to energy metabolism and found that subcortical morphological  
735 differences were not likely linked to prematurity or white matter injury alone, but that there was a linkage between  
736 brain metabolism and subcortical structural morphometry.<sup>58</sup> Stemming from these findings, we believe that  
737 subplate vulnerability in the prenatal and immediate post-natal period can be informative to understanding the  
738 subcortical dysmaturation seen in CHD infants. Within CHD individuals, it's been shown that preoperatively they  
739 have volumetric abnormalities present in the cerebellum and brainstem<sup>16</sup> and additionally that abnormal cerebellar  
740 growth has been linked with worse outcomes in expressive communication and the adaptive development quotient  
741 in CHD individuals.<sup>12</sup> Furthermore, there is an established link between subcortical morphological abnormalities  
742 and white matter vulnerability which can lead to injury and eventual worse neurodevelopmental outcomes.<sup>17,20</sup>  
743 With the mounting evidence of the importance of subcortical structures for proper brain development, and the  
744 subcortical structures' relationship to proper cortical development, inclusion of subcortical structures into our  
745 scoring system is necessary to characterize the entire picture of brain dysplasia. With nearly half of CHD cases still  
746 without a known genetic origin, identifying subtle cases of neurodevelopmental abnormalities in CHD individuals  
747 can better help us understand the downstream effects of CHD on brain development, ultimately furthering  
748 knowledge of the interplay between CHD and neurodevelopmental outcomes. Importantly, early interventional  
749 strategies have shown promise in helping CHD individuals with potential neurocognitive difficulties<sup>126</sup> and early  
750 identification of the most vulnerable through proper screening is necessary to identify and target therapies toward  
751 highest risk individuals.

## 752 **Limitations**

753 Our study does have some important limitations. The preterm and term CHD cohorts that we studied were  
754 heterogenous related to heart lesion subtypes. During this study, only a limited number of socio-demographic  
755 factors were prospectively collected and therefore analysis using these factors was unable to be carried out and  
756 future work correlating BDS score with pediatric/adolescent neurocognitive outcomes in relation to socio-  
757 demographic factors is needed. Our multi-site approach with different scanner platforms and vendors can lead to  
758 interscanner variance, but our secondary analyses did not find a correlation between scanner vendor or field  
759 strength and brain dysplasia score. Future work employing retrospective machine learning techniques like the  
760 empirical Bayes technique (Combat) can be used to reduce interscanner variance. Importantly, we were not able to  
761 measure extra-axial CSF fluid in the ECM imaging of the mouse mutants, which is an important component of the  
762 BDS score. Complete removal of CSF and infiltration of paraffin could have altered CSF volumes or the ventricle  
763 shape. With this in mind, we did not feel comfortable labeling these brain regions as containing CSF and instead  
764 labeled them as extra-axial space.

765

## 766 **Contributors**

767 Conceptualization: WTR, JVS, GG, VL,

768 Data Curation: WTR, JVS, GG, VL,

769 Manuscript Draft Preparation: WTR, JVS, GG, VL,

770 Manuscript Editing: WTR, JVS, GG, VL,

771 Statistical Analysis: VL, VS

772 Human Quantitative Scoring and Reads: SS, AP

773 Human Volumetric Segmentation: WTR,



774 Human Cardiac Lesion Characterization: JVS,  
775 Mouse Quantitative Scoring: WTR, YW, AP  
776 Mouse Volumetric Segmentation: RS,AP  
777 Supervision: CL, AP  
778 Verification of Underlying Data: WTR

#### 779 **Declaration of Interests**

780 The authors declare that there are no conflicts of interest.

#### 781 **Acknowledgments**

782 This work was supported by the Department of Defense (W81XWH-16-1-0613), the National Heart, Lung, and  
783 Blood Institute (R01 HL152740-1, R01 HL128818-05), and the National Heart, Lung and Blood Institute with  
784 National Institute on Aging (R01HL128818-05 S1). Southern California Clinical and Translational Sciences  
785 Institute (NCATS) through Grant UL1TR0001855. Its contents are solely the responsibility of the authors and do  
786 not necessarily represent the official views of the NIH. We also acknowledge Additional Ventures for support (AP,  
787 VR, RC). VR is supported by the Saban Research Institute, Additional Ventures Foundation and NIH-NHLBI  
788 K01HL153942. NT is supported by Children's Hospital Los Angeles Clinical Services Research Grant and the  
789 NINR K23 Grant 1K23NR019121-01A1.

790

#### 791 **Data Sharing Statement**

792 Preclinical mouse data can be made available upon request to corresponding author. Clinical data cannot be made  
793 public due to privacy issues, but limited data can be made available upon special request to the corresponding  
794 author with justification for the data request.

#### 795 **References**

- 796 1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. *J Am Coll Cardiol* 2002; **39**(12): 1890-  
797 900.
- 798 2. Sun R, Liu M, Lu L, Zheng Y, Zhang P. Congenital Heart Disease: Causes, Diagnosis, Symptoms, and  
799 Treatments. *Cell Biochemistry and Biophysics* 2015; **72**(3): 857-60.
- 800 3. Rollins CK, Newburger JW, Roberts AE. Genetic contribution to neurodevelopmental outcomes in  
801 congenital heart disease: are some patients predetermined to have developmental delay? *Current Opinion in*  
802 *Pediatrics* 2017; **29**(5): 529-33.
- 803 4. Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital  
804 heart disease probands. *Nature Genetics* 2017; **49**(11): 1593-601.
- 805 5. Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental  
806 and other congenital anomalies. *Science* 2015; **350**(6265): 1262-6.
- 807 6. Ji W, Ferdman D, Copel J, et al. De novo damaging variants associated with congenital heart diseases  
808 contribute to the connectome. *Scientific Reports* 2020; **10**(1).
- 809 7. Hayek C, Rajagopalan V, Meouchy J, et al. Ventricular and total brain volumes in infants with congenital  
810 heart disease: a longitudinal study. *Journal of Perinatology* 2020; **40**(9): 1383-8.
- 811 8. Bonthron AF, Dimitrova R, Chew A, et al. Individualized brain development and cognitive outcome in  
812 infants with congenital heart disease. *Brain Commun* 2021; **3**(2): fcab046.

- 813 9. Bonthrone AF, Kelly CJ, Ng IHX, Counsell SJ. MRI studies of brain size and growth in individuals with  
814 congenital heart disease. *Translational Pediatrics* 2021; **10**(8): 2171-81.
- 815 10. Stinnett GR, Lin S, Korotcov AV, et al. Microstructural Alterations and Oligodendrocyte Dysmaturation  
816 in White Matter After Cardiopulmonary Bypass in a Juvenile Porcine Model. *Journal of the American Heart*  
817 *Association* 2017; **6**(8): e005997.
- 818 11. Morton PD, Korotcova L, Lewis BK, et al. Abnormal neurogenesis and cortical growth in congenital heart  
819 disease. *Science translational medicine* 2017; **9**(374): eaah7029.
- 820 12. Wong A, Chavez T, O'Neil S, et al. Synchronous Aberrant Cerebellar and Opercular Development in  
821 Fetuses and Neonates with Congenital Heart Disease: Correlation with Early Communicative Neurodevelopmental  
822 Outcomes, Initial Experience. *American Journal of Perinatology Reports* 2017; **7**(01): e17-e27.
- 823 13. von Rhein M, Buchmann A, Hagmann C, et al. Brain volumes predict neurodevelopment in adolescents  
824 after surgery for congenital heart disease. *Brain : a journal of neurology* 2014; **137**(Pt 1): 268-76.
- 825 14. von Rhein M, Buchmann A, Hagmann C, et al. Severe congenital heart defects are associated with global  
826 reduction of neonatal brain volumes. *The Journal of pediatrics* 2015; **167**(6): 1259-63. e1.
- 827 15. Owen M, Shevell M, Donofrio M, et al. Brain volume and neurobehavior in newborns with complex  
828 congenital heart defects. *J Pediatr* 2014; **164**(5): 1121-7 e1.
- 829 16. Ortinau C, Beca J, Lambeth J, et al. Regional alterations in cerebral growth exist preoperatively in infants  
830 with congenital heart disease. *The Journal of Thoracic and Cardiovascular Surgery* 2012; **143**: 1264-70.
- 831 17. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental  
832 disturbances. *Lancet neurology* 2009; **8**(1): 110-24.
- 833 18. Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and  
834 pathogenesis. *Seminars in Pediatric Neurology* 1998; **5**: 135-51.
- 835 19. Ligam P, Haynes RL, Folkerth RD, et al. Thalamic damage in periventricular leukomalacia: novel  
836 pathologic observations relevant to cognitive deficits in survivors of prematurity. *Pediatr Res* 2009; **65**(5): 524-9.
- 837 20. Wisnowski JL, Ceschin RC, Choi SY, et al. Reduced thalamic volume in preterm infants is associated  
838 with abnormal white matter metabolism independent of injury. *Neuroradiology* 2015; **57**(5): 515-25.
- 839 21. Panigrahy A, Lee V, Ceschin R, et al. Brain Dysplasia Associated with Ciliary Dysfunction in Infants with  
840 Congenital Heart Disease. *The Journal of Pediatrics* 2016; **178**: 141-8. e1.
- 841 22. Ceschin R, Zahner A, Reynolds W, et al. A computational framework for the detection of subcortical brain  
842 dysmaturation in neonatal MRI using 3D Convolutional Neural Networks. *NeuroImage* 2018; **178**: 183-97.
- 843 23. Heye KN, Knirsch W, Latal B, et al. Reduction of brain volumes after neonatal cardiopulmonary bypass  
844 surgery in single-ventricle congenital heart disease before Fontan completion. *Pediatric research* 2018; **83**(1): 63-  
845 70.
- 846 24. von Rhein M, Buchmann A, Hagmann C, et al. Severe congenital heart defects are associated with global  
847 reduction of neonatal brain volumes. *The Journal of pediatrics* 2015; **167**(6): 1259-63. e1.
- 848 25. Watson CG, Stopp C, Wypij D, Newburger JW, Rivkin MJ. Reduced cortical volume and thickness and  
849 their relationship to medical and operative features in post-Fontan children and adolescents. *Pediatric research*  
850 2017; **81**(6): 881-90.
- 851 26. Alablani FJ, Chan HSA, Beishon L, et al. Paediatric brain MRI findings following congenital heart  
852 surgery: a systematic review. *Archives of disease in childhood* 2022; **107**(9): 818-25.
- 853 27. Bhattacharjee I, Mohamed MA, Nandakumar V, Friedman NR, Ruggieri P, Aly H. Scoring of brain  
854 magnetic resonance imaging and neurodevelopmental outcomes in infants with congenital heart disease. *Early*  
855 *human development* 2022; **169**: 105574.
- 856 28. Brossard-Racine M, du Plessis A, Vezina G, et al. Brain injury in neonates with complex congenital heart  
857 disease: what is the predictive value of MRI in the fetal period? *Am J Neuroradiol* 2016; **37**(7): 1338-46.

- 858 29. Dijkhuizen EI, de Munck S, de Jonge RCJ, et al. Early brain magnetic resonance imaging findings and  
859 neurodevelopmental outcome in children with congenital heart disease: A systematic review. *Developmental*  
860 *Medicine & Child Neurology* 2023.
- 861 30. Li Y, Yin S, Fang J, et al. Neurodevelopmental delay with critical congenital heart disease is mainly from  
862 prenatal injury not infant cardiac surgery: current evidence based on a meta - analysis of functional magnetic  
863 resonance imaging. *Ultrasound in Obstetrics & Gynecology* 2015; **45**(6): 639-48.
- 864 31. McCarthy AL, Winters ME, Busch DR, et al. Scoring system for periventricular leukomalacia in infants  
865 with congenital heart disease. *Pediatric research* 2015; **78**(3): 304-9.
- 866 32. Mulkey SB, Swearingen CJ, Melguizo MS, et al. Multi-tiered analysis of brain injury in neonates with  
867 congenital heart disease. *Pediatric cardiology* 2013; **34**: 1772-84.
- 868 33. Stegeman R, Feldmann M, Claessens NHP, et al. A uniform description of perioperative brain MRI  
869 findings in infants with severe congenital heart disease: results of a European collaboration. *Am J Neuroradiol*  
870 2021; **42**(11): 2034-9.
- 871 34. Panigrahy A, Lee V, Ceschin R, et al. Brain Dysplasia Associated with Ciliary Dysfunction in Infants with  
872 Congenital Heart Disease. *The Journal of pediatrics* 2016.
- 873 35. Ceschin R, Zahner A, Reynolds W, et al. A computational framework for the detection of subcortical brain  
874 dysmaturation in neonatal MRI using 3D Convolutional Neural Networks. *NeuroImage* 2018.
- 875 36. Gabriel GC, Salamacha N, Reynolds WT, et al. Characterization of Neurodevelopmental Defects  
876 Associated With a Mouse Model of Hypoplastic Left Heart Syndrome. *Circulation* 2018; **138**(Suppl\_1): A16609-  
877 A.
- 878 37. Panigrahy A, Ceschin R, Lee V, et al. Respiratory Ciliary Motion Defect Predict Regional Brain  
879 Abnormalities and Increased Extra Axial CSF Fluid in Neonates With Complex Congenital Heart Disease.  
880 *Circulation* 2014; **130**(Suppl 2): A16570-A.
- 881 38. Panigrahy A, Votava-Smith J, Lee V, et al. Abnormal Brain Connectivity and Poor Neurodevelopmental  
882 Outcome in Congenital Heart Disease Patients With Subtle Brain Dysplasia. *Circulation* 2015; **132**(Suppl 3):  
883 A16541-A.
- 884 39. Subramanian S, Soundara Rajan D, Gaesser J, Wen-Ya Lo C, Panigrahy A. Olfactory bulb and olfactory  
885 tract abnormalities in acrocallosal syndrome and Greig cephalopolysyndactyly syndrome. *Pediatric Radiology*  
886 2019; **49**(10): 1368-73.
- 887 40. Votava-Smith JK, Schmithorst VJ, Tran N, et al. Impaired Pre-Operative Cerebral Autoregulation is  
888 Associated With Functional Brain Dysmaturation in Neonatal Congenital Heart Disease. *Circulation* 2017;  
889 **136**(suppl\_1): A15580-A.
- 890 41. Votava-Smith JK, Gaesser J, Harbison AL, et al. Clinical factors associated with microstructural  
891 connectome related brain dysmaturation in term neonates with congenital heart disease. *Frontiers in neuroscience*  
892 2022; **16**: 952355.
- 893 42. Limperopoulos C, Tworetzky W, McElhinney DB, et al. Brain volume and metabolism in fetuses with  
894 congenital heart disease: evaluation with quantitative magnetic resonance imaging and spectroscopy. *Circulation*  
895 2010; **121**: 26-33.
- 896 43. Sun L, Macgowan CK, Sled JG, et al. Reduced fetal cerebral oxygen consumption is associated with  
897 smaller brain size in fetuses with congenital heart disease. *Circulation* 2015; **131**: 1313-23.
- 898 44. Liu X, Yagi H, Saeed S, et al. The complex genetics of hypoplastic left heart syndrome. *Nature genetics*  
899 2017; **49**(7): 1152-9.
- 900 45. Thu CA, Chen WV, Rubinstein R, et al. Single-cell identity generated by combinatorial homophilic  
901 interactions between  $\alpha$ ,  $\beta$ , and  $\gamma$  protocadherins. *Cell* 2014; **158**(5): 1045-59.
- 902 46. Mountoufaris G, Chen WV, Hirabayashi Y, et al. Multicluster Pcdh diversity is required for mouse  
903 olfactory neural circuit assembly. *Science* 2017; **356**(6336): 411-4.

- 904 47. Anitha A, Thanseem I, Nakamura K, et al. Protocadherin  $\alpha$  (PCDHA) as a novel susceptibility gene for  
905 autism. *Journal of Psychiatry and Neuroscience* 2013; **38**(3): 192-8.
- 906 48. Witteveen JS, Willemsen MH, Dombroski TC, et al. Haploinsufficiency of MeCP2-interacting  
907 transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical  
908 integrity. *Nature Genetics* 2016; **48**(8): 877-87.
- 909 49. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by  
910 mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nature genetics* 1999; **23**(2): 185-8.
- 911 50. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of  
912 neuronal gene chromatin throughout neurogenesis. *Cell* 2005; **121**(4): 645-57.
- 913 51. Gao Z, Ure K, Ding P, et al. The master negative regulator REST/NRSF controls adult neurogenesis by  
914 restraining the neurogenic program in quiescent stem cells. *Journal of Neuroscience* 2011; **31**(26): 9772-86.
- 915 52. Wisnowski JL, Schmithorst VJ, Rosser T, et al. Magnetic resonance spectroscopy markers of axons and  
916 astrogliosis in relation to specific features of white matter injury in preterm infants. *Neuroradiology* 2014; **56**: 771-  
917 9.
- 918 53. Wisnowski JL, Blüml S, Paquette L, et al. Altered Glutamatergic Metabolism Associated with Punctate  
919 White Matter Lesions in Preterm Infants. *Plos One* 2013; **8**(2).
- 920 54. Blüml S, Wisnowski JL, Nelson MD, Paquette L, Panigrahy A. Metabolic maturation of white matter is  
921 altered in preterm infants. *Plos One* 2014; **9**: e85829.
- 922 55. Blüml S, Wisnowski JL, Nelson Jr MD, Paquette L, Panigrahy A. Metabolic maturation of white matter is  
923 altered in preterm infants. *Plos One* 2014; **9**(1): e85829.
- 924 56. Blüml S, Wisnowski JL, Nelson MD, et al. Metabolic maturation of the human brain from birth through  
925 adolescence: insights from in vivo magnetic resonance spectroscopy. *Cerebral Cortex* 2013; **23**(12): 2944-55.
- 926 57. Ceschin R, Wisnowski JL, Paquette LB, Nelson MD, Blüml S, Panigrahy A. Developmental synergy  
927 between thalamic structure and interhemispheric connectivity in the visual system of preterm infants. *NeuroImage:*  
928 *Clinical* 2015.
- 929 58. Gertsvolf N, Votava-Smith JK, Ceschin R, et al. Association between Subcortical Morphology and  
930 Cerebral White Matter Energy Metabolism in Neonates with Congenital Heart Disease. *Scientific reports* 2018; **8**.
- 931 59. Harbison AL, Votava-Smith JK, Del Castillo S, et al. Clinical Factors Associated with Cerebral  
932 Metabolism in Term Neonates with Congenital Heart Disease. *The Journal of Pediatrics* 2017.
- 933 60. Paquette LB, Votava-Smith JK, Ceschin R, et al. Abnormal development of thalamic microstructure in  
934 premature neonates with congenital heart disease. *Pediatric cardiology* 2015; **36**(5): 960-9.
- 935 61. Schmithorst VJ, Votava - Smith JK, Tran N, et al. Structural network topology correlates of  
936 microstructural brain dysmaturation in term infants with congenital heart disease. *Human brain mapping* 2018;  
937 **39**(11): 4593-610.
- 938 62. Wisnowski JL, Blüml S, Paquette L, et al. Altered glutamatergic metabolism associated with punctate  
939 white matter lesions in preterm infants. *Plos One* 2013; **8**(2): e56880.
- 940 63. Wisnowski JL, Schmithorst VJ, Rosser T, et al. Magnetic resonance spectroscopy markers of axons and  
941 astrogliosis in relation to specific features of white matter injury in preterm infants. *Neuroradiology* 2014: 1-9.
- 942 64. Paquette LB, Wisnowski JL, Ceschin R, et al. Abnormal cerebral microstructure in premature neonates  
943 with congenital heart disease. *AJNR American journal of neuroradiology* 2013; **34**: 2026-33.
- 944 65. Panigrahy A, Ceschin R, Lee V, et al. Respiratory Ciliary Motion Defect Predict Regional Brain  
945 Abnormalities and Increased Extra Axial CSF Fluid in Neonates With Complex Congenital Heart Disease.  
946 *Circulation* 2014; **130**(suppl\_2): A16570-A.

- 947 66. Panigrahy A, Votava-Smith J, Lee V, et al. Abnormal Brain Connectivity and Poor Neurodevelopmental  
948 Outcome in Congenital Heart Disease Patients With Subtle Brain Dysplasia. *Circulation* 2015; **132**(suppl\_3):  
949 A16541-A.
- 950 67. Votava-Smith JK, Tran N, Abbott J, et al. Impaired Cerebral Autoregulation is Associated With Brain  
951 Abnormalities in Neonatal Congenital Heart Disease: Initial Experience. *Circulation* 2016; **134**(suppl\_1): A18081-  
952 A.
- 953 68. Lao Y, Wang Y, Shi J, et al. Thalamic alterations in preterm neonates and their relation to ventral striatum  
954 disturbances revealed by a combined shape and pose analysis. *Brain Structure and Function* 2014: 1-20.
- 955 69. Shi J, Wang Y, Ceschin R, et al. A multivariate surface-based analysis of the putamen in premature  
956 newborns: regional differences within the ventral striatum. *Plos One* 2013; **8**(7): e66736.
- 957 70. Serag A, Aljabar P, Ball G, et al. Construction of a consistent high-definition spatio-temporal atlas of the  
958 developing brain using adaptive kernel regression. *Neuroimage* 2012; **59**(3): 2255-65.
- 959 71. Votava-Smith JK, Gaesser J, Harbison AL, et al. Clinical Factors Associated with Microstructural  
960 Connectome Related Brain Dysmaturation in Term Neonates with Congenital Heart Disease. Cold Spring Harbor  
961 Laboratory; 2022.
- 962 72. Li Y, Klena NT, Gabriel GC, et al. Global genetic analysis in mice unveils central role for cilia in  
963 congenital heart disease. *Nature* 2015; **521**(7553): 520-4.
- 964 73. Damerla RR, Cui C, Gabriel GC, et al. Novel Jbts17 mutant mouse model of Joubert syndrome with cilia  
965 transition zone defects and cerebellar and other ciliopathy related anomalies. *Hum Mol Genet* 2015; **24**(14): 3994-  
966 4005.
- 967 74. Latal B, Patel P, Liamlahi R, Knirsch W, Tuura ROG, von Rhein M. Hippocampal volume reduction is  
968 associated with intellectual functions in adolescents with congenital heart disease. *Pediatric research* 2016; **80**(4):  
969 531.
- 970 75. Fontes K, Rohlicek CV, Saint - Martin C, et al. Hippocampal alterations and functional correlates in  
971 adolescents and young adults with congenital heart disease. *Human brain mapping* 2019.
- 972 76. Wu Y, Kapse K, Jacobs M, et al. Association of maternal psychological distress with in utero brain  
973 development in fetuses with congenital heart disease. *JAMA pediatrics* 2020; **174**(3): e195316-e.
- 974 77. BOLDUC ME, Limperopoulos C. Neurodevelopmental outcomes in children with cerebellar  
975 malformations: a systematic review. *Developmental Medicine & Child Neurology* 2009; **51**(4): 256-67.
- 976 78. Stoodley CJ. The cerebellum and neurodevelopmental disorders. *The Cerebellum* 2016; **15**(1): 34-7.
- 977 79. Zwicker JG, Miller SP, Grunau RE, et al. Smaller cerebellar growth and poorer neurodevelopmental  
978 outcomes in very preterm infants exposed to neonatal morphine. *The Journal of pediatrics* 2016; **172**: 81-7. e2.
- 979 80. Badaly D, Beers SR, Ceschin R, et al. Cerebellar and Prefrontal Structures Associated with Executive  
980 Functioning in Pediatric Patients with Congenital Heart Defects. *medRxiv* 2021.
- 981 81. Ramphal B, Whalen DJ, Kenley JK, et al. Brain connectivity and socioeconomic status at birth and  
982 externalizing symptoms at age 2 years. *Developmental cognitive neuroscience* 2020; **45**: 100811.
- 983 82. Graham AM, Buss C, Rasmussen JM, et al. Implications of newborn amygdala connectivity for fear and  
984 cognitive development at 6-months-of-age. *Developmental cognitive neuroscience* 2016; **18**: 12-25.
- 985 83. Taoudi-Benchekroun Y, Christiaens D, Grigorescu I, et al. Predicting age and clinical risk from the  
986 neonatal connectome. *NeuroImage* 2022; **257**: 119319.
- 987 84. Bhroin MN, Seada SA, Bonthron AF, et al. Reduced structural connectivity in cortico-striatal-thalamic  
988 network in neonates with congenital heart disease. *NeuroImage: Clinical* 2020; **28**: 102423.
- 989 85. Haber SN. Corticostriatal circuitry. *Dialogues in clinical neuroscience* 2022.
- 990 86. Gordon EM, Laumann TO, Marek S, et al. Individualized functional subnetworks connect human striatum  
991 and frontal cortex. *Cerebral Cortex* 2022; **32**(13): 2868-84.



- 992 87. Giessel AJ, Datta SR. Olfactory maps, circuits and computations. *Current opinion in neurobiology* 2014;  
993 **24**: 120-32.
- 994 88. Millhouse OE, Heimer L. Cell configurations in the olfactory tubercle of the rat. *Journal of Comparative*  
995 *Neurology* 1984; **228**(4): 571-97.
- 996 89. Murata K, Kanno M, Ieki N, Mori K, Yamaguchi M. Mapping of learned odor-induced motivated  
997 behaviors in the mouse olfactory tubercle. *Journal of Neuroscience* 2015; **35**(29): 10581-99.
- 998 90. Fudge JL, Kunishio K, Walsh P, Richard C, Haber SN. Amygdaloid projections to ventromedial striatal  
999 subterritories in the primate. *Neuroscience* 2002; **110**(2): 257-75.
- 1000 91. Russchen FT, Bakst I, Amaral DG, Price JL. The amygdalostratial projections in the monkey. An  
1001 anterograde tracing study. *Brain research* 1985; **329**(1-2): 241-57.
- 1002 92. Kelley AE, Domesick VB, Nauta WJH. The amygdalostratial projection in the rat—an anatomical study  
1003 by anterograde and retrograde tracing methods. *Neuroscience* 1982; **7**(3): 615-30.
- 1004 93. Krettek J, Price J. Amygdaloid projections to subcortical structures within the basal forebrain and  
1005 brainstem in the rat and cat. *Journal of Comparative Neurology* 1978; **178**(2): 225-53.
- 1006 94. Scott JW, McBride RL, Schneider SP. The organization of projections from the olfactory bulb to the  
1007 piriform cortex and olfactory tubercle in the rat. *Journal of Comparative Neurology* 1980; **194**(3): 519-34.
- 1008 95. Kosel KC, Van Hoesen GW, West JR. Olfactory bulb projections to the parahippocampal area of the rat.  
1009 *Journal of Comparative Neurology* 1981; **198**(3): 467-82.
- 1010 96. Zhang Z, Zhang H, Wen P, et al. Whole-brain mapping of the inputs and outputs of the medial part of the  
1011 olfactory tubercle. *Frontiers in Neural Circuits* 2017; **11**: 52.
- 1012 97. Leisman G, Braun-Benjamin O, Melillo R. Cognitive-motor interactions of the basal ganglia in  
1013 development. *Frontiers in systems neuroscience* 2014; **8**: 16.
- 1014 98. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus  
1015 accumbens–olfactory tubercle complex. *Brain research reviews* 2007; **56**(1): 27-78.
- 1016 99. Seubert J, Freiherr J, Frasnelli J, Hummel T, Lundström JN. Orbitofrontal cortex and olfactory bulb  
1017 volume predict distinct aspects of olfactory performance in healthy subjects. *Cerebral Cortex* 2013; **23**(10): 2448-  
1018 56.
- 1019 100. De Smet HJ, Paquier P, Verhoeven J, Mariën P. The cerebellum: its role in language and related cognitive  
1020 and affective functions. *Brain and language* 2013; **127**(3): 334-42.
- 1021 101. Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia.  
1022 *Nature neuroscience* 2005; **8**(11): 1491-3.
- 1023 102. Bostan AC, Dum RP, Strick PL. The basal ganglia communicate with the cerebellum. *Proceedings of the*  
1024 *national academy of sciences* 2010; **107**(18): 8452-6.
- 1025 103. O'Doherty JP, Dayan P, Friston K, Critchley H, Dolan RJ. Temporal difference models and reward-related  
1026 learning in the human brain. *Neuron* 2003; **38**(2): 329-37.
- 1027 104. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. *Current*  
1028 *opinion in neurobiology* 2002; **12**(2): 217-22.
- 1029 105. Yagi H, Liu X, Gabriel GC, et al. The Genetic Landscape of Hypoplastic Left Heart Syndrome. *Pediatr*  
1030 *Cardiol* 2018; **39**(6): 1069-81.
- 1031 106. Tiana M, Acosta-Iborra B, Puente-Santamaria L, et al. The SIN3A histone deacetylase complex is  
1032 required for a complete transcriptional response to hypoxia. *Nucleic Acids Res* 2018; **46**(1): 120-33.
- 1033 107. Asahina H, Masuba A, Hirano S, Yuri K. Distribution of protocadherin 9 protein in the developing mouse  
1034 nervous system. *Neuroscience* 2012; **225**: 88-104.

- 1035 108. Wu Y, Jin X, Zhang Y, Zheng J, Yang R. Genetic and epigenetic mechanisms in the development of  
1036 congenital heart diseases. *World J Pediatr Surg* 2021; **4**(2): e000196.
- 1037 109. Bruneau BG. Signaling and transcriptional networks in heart development and regeneration. *Cold Spring*  
1038 *Harb Perspect Biol* 2013; **5**(3): a008292.
- 1039 110. Zhang QJ, Liu ZP. Histone methylations in heart development, congenital and adult heart diseases.  
1040 *Epigenomics* 2015; **7**(2): 321-30.
- 1041 111. Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital  
1042 heart disease: evaluation and management: a scientific statement from the American Heart Association. *Circulation*  
1043 2012; **126**(9): 1143-72.
- 1044 112. Newburger JW, Sleeper LA, Bellinger DC, et al. Early Developmental Outcome in Children With  
1045 Hypoplastic Left Heart Syndrome and Related Anomalies. *Circulation* 2012; **125**(17): 2081-91.
- 1046 113. Sananes R, Manlhiot C, Kelly E, et al. Neurodevelopmental outcomes after open heart operations before 3  
1047 months of age. *Ann Thorac Surg* 2012; **93**(5): 1577-83.
- 1048 114. von Rhein M, Dimitropoulos A, Valsangiacomo Buechel ER, Landolt MA, Latal B. Risk factors for  
1049 neurodevelopmental impairments in school-age children after cardiac surgery with full-flow cardiopulmonary  
1050 bypass. *J Thorac Cardiovasc Surg* 2012; **144**(3): 577-83.
- 1051 115. Naef N, Liamlahi R, Beck I, et al. Neurodevelopmental Profiles of Children with Congenital Heart  
1052 Disease at School Age. *J Pediatr* 2017; **188**: 75-81.
- 1053 116. Verrall CE, Blue GM, Loughran-Fowlds A, et al. 'Big issues' in neurodevelopment for children and adults  
1054 with congenital heart disease. *Open Heart* 2019; **6**(2): e000998.
- 1055 117. Sood E, Jacobs JP, Marino BS. Optimising neurodevelopmental and psychosocial outcomes for survivors  
1056 with CHD: a research agenda for the next decade. *Cardiol Young* 2021; **31**(6): 873-5.
- 1057 118. Jacobsen RM. Outcomes in Adult Congenital Heart Disease: Neurocognitive Issues and Transition of  
1058 Care. *Pediatr Clin North Am* 2020; **67**(5): 963-71.
- 1059 119. Marelli A, Miller SP, Marino BS, Jefferson AL, Newburger JW. Brain in Congenital Heart Disease Across  
1060 the Lifespan: The Cumulative Burden of Injury. *Circulation* 2016; **133**(20): 1951-62.
- 1061 120. Bellinger DC, Wypij D, Rivkin MJ, et al. Adolescents with d-transposition of the great arteries corrected  
1062 with the arterial switch procedure: neuropsychological assessment and structural brain imaging. *Circulation* 2011;  
1063 **124**(12): 1361-9.
- 1064 121. Schaefer C, von Rhein M, Knirsch W, et al. Neurodevelopmental outcome, psychological adjustment, and  
1065 quality of life in adolescents with congenital heart disease. *Dev Med Child Neurol* 2013; **55**(12): 1143-9.
- 1066 122. Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of Congenital Heart Disease. *Circulation*  
1067 *Research* 2013; **112**(4): 707-20.
- 1068 123. Zaidi S, Brueckner M. Genetics and Genomics of Congenital Heart Disease. *Circulation Research* 2017;  
1069 **120**(6): 923-40.
- 1070 124. Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited Risk Factors and Congenital Cardiovascular  
1071 Defects: Current Knowledge. *Circulation* 2007; **115**(23): 2995-3014.
- 1072 125. Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart  
1073 disease. *Nature* 2013; **498**(7453): 220-3.
- 1074 126. Cassidy AR, Butler SC, Briend J, et al. Neurodevelopmental and psychosocial interventions for  
1075 individuals with CHD: a research agenda and recommendations from the Cardiac Neurodevelopmental Outcome  
1076 Collaborative. *Cardiol Young* 2021; **31**(6): 888-99.


1077

1078

1079

1080 **Figure and Figure Legends**


1081



1082

1083 **Figure 1. Recruitment Flowchart and Subject Numbers.** Study initially consisted of 534 subjects which were  
1084 scored using the brain dysplasia score (BDS). Initial subjects consisted of 307 term and 116 pre-term individuals.

1085



1086


1087 **Figure 2. Hippocampal Abnormalities Were Similar Among Human and Mouse.** Panel (a)(b)(c) and (d)

1088 demonstrate abnormal hypoplastic and/or malrotated hippocampi in infants with CHD which comparable

1089 abnormalities noted in the mouse mutant (e). A mouse control is shown for comparison in (f) depicts an abnormal.

1090 Panel (b)

1091




1092

1093 **Figure 3. Consistent Olfactory Bulb Phenotype is Visible Among Human and Mouse.** (a) Human control  
1094 subject exhibits normal olfactory bulb size and structure. (b) Mouse control showing olfactory bulb with normal  
1095 shape and size. (c) HLHS human subject with aplastic olfactory bulbs. (d) Mouse with Congenital heart disease  
1096 with hypoplastic olfactory bulb.

1097




1098



1099

1100 **Figure 4. Cerebellar Abnormalities Seen in Both Human and Mouse.** Panels (a) and (b) depict a human subject  
1101 with HLHS compared to a healthy control. The cerebellum of the HLHS subject is hypoplastic shows  
1102 dysmaturation. Panels (c) and (d) show a mouse with HLHS and a normal control. The cerebellum of the HLHS  
1103 mutant displayed hypoplasia and a lesser number of cerebellar fissures. (e) Average number of cerebellar fissures  
1104 among mouse groupings. (f) Human neonatal cerebellar residual volumes with gestational age regressed out.

1105



1106

1107

**Figure 5. Phenotype Mouse Screen Recovered Mutant Mice with Defects in Cardiac, Brain and Craniofacial.**

1108

(a) From the original phenotype screen 390 mutant lines were identified. Of those 390 lines 249 had CHD and of

1109

those, 174 and 62 had craniofacial and severe brain anomalies, respectively. Of the 40 lines that didn't have CHD,

1110

33 had craniofacial and 7 had severe brain anomalies.

1111

(b) Three major groupings, congenital heart disease,

1112


craniofacial anomalies, and server brain anomalies, identified from the original phenotype screen and their

1113

relationship to one another. The highest overlap between two conditions is congenital heart disease and craniofacial

1114

anomalies at approximately 29% of the original 390 mutants identified.




1115

1116 **Figure 6. Mouse RNA Sequencing Analysis Shows Significant Difference in Gene Expression.** (a) Genes  
1117 associated with learning and memory showed lesser expression in control mice compared to Ohia mutant mice. (b)  
1118 Genes associated with feeding behavior showed an abnormal pattern in Ohia mice. Ohia mice showed a pattern of  
1119 expression that was opposite compared control mice at both time points. (c) Genes associated with neuronal  
1120 differentiation showed a opposite pattern of expression in Ohia mutant mice compared to controls. (d) Genes  
1121 associated with synaptic transmission had a different expression pattern in Ohia mutant mice compared to controls.

1122

1123 **Supplemental Figure Legends**

## Total Brain Dysplasia Score



1124

1125 **Supplemental Figure 1. Components of Human Brain Dysplasia Scoring Criteria.** Our brain dysplasia scoring  
 1126 criteria consisted of 13 distinct observations. Supratentorial extra-axial fluid was assessed for normality, cerebellar  
 1127 hemisphere and vermis were assessed for hypoplasia and dysplasia, right and left olfactory bulb and olfactory  
 1128 sulcus were examined for any abnormalities. Additionally, the hippocampus, corpus callosum, choroid plexus, and  
 1129 brainstem were checked for abnormalities.

1130

## Composite Brain Injury Score

$$CBIS = \begin{matrix} \text{Hemorrhage} \\ \begin{Bmatrix} 0 \\ 1 \end{Bmatrix} \end{matrix} + \begin{matrix} \text{Hypoxic-Ischemic} \\ \begin{Bmatrix} 0 \\ 1 \end{Bmatrix} \end{matrix} + \begin{matrix} \text{Infarct} \\ \begin{Bmatrix} 0 \\ 1 \end{Bmatrix} \end{matrix} + \begin{matrix} \text{P/WMI} \\ \begin{Bmatrix} 0 \\ 1 \end{Bmatrix} \end{matrix}$$


Brain Injury Composite Dichotomized:  
If Composite Brain Injury Score > 0 then → 1, else → 0

1131

1132 **Supplemental Figure 2. Components of Composite Brain Injury Score.** Brain injury score was composed of  
1133 four measures: hemorrhage, infarct, hypoxic ischemia, and perinatal white matter injury. Brain injury score was  
1134 binary, if any injury was present in the above measures, the subject was considered to have a brain injury.

1135






1136

1137 **Supplemental Figure 3. Flow Diagram for NeBSS, a Semi-automated Neonatal Segmentation Pipeline.**

1138 Briefly, subject MR images are input into NeBSS which has two branches. Branch A uses the Albert Neonatal  
1139 Atlas and outputs 50 distinct volumetric brain structures in the subject space. Branch B uses the Serag Neonatal  
1140 Brain Atlas probability maps to output 10 volumetric brain regions.

1141




1142

1143 **Supplemental Figure 4. Flow Diagram of Sample Preparation, ECM Analysis, and Volumetric Analysis.**

1144 Samples selected for analysis were first necropsied. Post-necropsy samples were dehydrated using a Sakura Tissue  
1145 Tek system and processed on the ECM machine. Samples were then manually segmented using ITK-Snap before  
1146 volumetric results were analyzed.

1147



1148

1149 **Supplemental Figure 5. Necropsy Among Mutant Mice Showed Variety and Differing Degree of Severity of**


1150 **Malformations.** Mice in the mouse screen presented with craniofacial anomalies with varying degrees of severity.

1151 More mild forms of errant craniofacial anatomy presented with mild defects in the ears and eyes. Moderate forms

1152 presented as more severe ear and eye defects as well as a shortened snout. Lastly, severe defects presented with

1153 large structural defects in the craniofacial anatomy, often with underlying structural brain defects as well.


1154



1155

1156 **Supplemental Figure 6. Individual Structures Showed a Range of Abnormality in Screen Mice.** Episcopic  
1157 Fluorescence Image Capture (ECM) was carried out on prepared mouse brains. Samples presented with varying  
1158 degrees of abnormalities. Three major structures analyzed were olfactory bulbs, cerebellum, and hippocampus.  
1159 Within each structure, mice had a variety of defects including aplasia, hypoplasia, and dysplasia.

1160




1161

1162 **Supplemental Figure 7. Varying Degree of Cerebral Abnormalities Present in Screen Mice.** ECM analysis  
1163 found that mice had varying degrees of severity of cerebral abnormalities including holoprosencephaly and cerebral  
1164 hypoplasia.

1165






1166

1167 **Supplemental Figure 8. Crispr/Cas9 Figure Mutant Animals Showed Similar Phenotype to Screen Mice.**

1168 Using ECM, Crispr/Cas9 mutants were analyzed and show similar phenotypes seen in mutant mice recovered from  
1169 the phenotype screen. A similar pattern of dysplasia and aplasia were seen in the cerebellum, olfactory bulb and  
1170 hippocampus of mice recovered in the screen.

1171

1172



1173

1174 **Supplemental Figure 9. Holoprosencephaly and Hippocampal Malformations Seen in Human and Mouse.** A,  
1175 Alobar holoprosencephaly seen in Sap130 CRISPR/Cas9 deletion mouse. B, Lobar holoprosencephaly seen in  
1176 Sap130/Pcdha9 double CRISPR/Cas9 deletion mouse. C, Pcdha9 CRISPR/Cas9 deletion mouse displaying cerebral  
1177 hypoplasia and dysmaturation as well as hippocampal abnormalities. D, Control mouse showing normal cortical  
1178 and hippocampal anatomy. E, Sap130/Pcdha9 double mutant mouse exhibiting cortical, corpus callosum, and  
1179 hippocampal abnormalities. F, Lobar holoprosencephaly and hippocampal malformations observed in human  
1180 subjects with HLHS.

**Table 1: Incidence of Subcortical Brain Dysmaturation in Preterm/Term CHD And Controls**

BDS Abnormalities (Dichotomous)	Preterm CHD (n = 69)	Preterm Non- CHD (n = 51)	Comparison	Term CHD (n = 263)	Term Control (n = 93)	Comparison
	Number of Subjects with Abnormality (%)		p-value	Number of Subjects with Abnormality (%)		p-value
Bilateral Cerebellar Hemispheric Hypoplasia	13 (18.84%)	1 (1.96%)	<b>0.0049</b>	30 (11.41%)	0 (0.00%)	<b>0.0006</b>
Bilateral Cerebellar Hemispheric Dysplasia	7 (10.14%)	1 (1.96%)	0.0607	15 (5.70%)	0 (0.00%)	<b>0.0133</b>
Cerebellar Vermis Hypoplasia	18 (26.09%)	3 (5.88%)	<b>0.0040</b>	58 (22.05%)	0 (0.00%)	<b>&lt;0.0001</b>
Cerebellar Vermis Dysplasia	9 (13.04%)	0 (0.00%)	<b>0.0049</b>	23 (8.75%)	0 (0.00%)	<b>0.0019</b>
<i>Dichotomized Cerebellar Composite</i>	26 (37.68%)	3 (5.88%)	<b>&lt;0.0001</b>	75 (28.52%)	0 (0.00%)	<b>&lt;0.0001</b>
Right Olfactory Bulb	24 (34.78%)	4 (7.84%)	<b>&lt;0.0001</b>	127 (48.29%)	8 (8.60%)	<b>&lt;0.0001</b>
Left Olfactory Bulb	25 (36.23%)	4 (7.84%)	<b>&lt;0.0001</b>	126 (47.91%)	9 (9.68%)	<b>&lt;0.0001</b>
Right Olfactory Sulcus	23 (33.33%)	1 (1.96%)	<b>&lt;0.0001</b>	109 (41.44%)	3 (3.23%)	<b>&lt;0.0001</b>
Left Olfactory Sulcus	23 (33.33%)	1 (1.96%)	<b>&lt;0.0001</b>	109 (41.44%)	2 (2.15%)	<b>&lt;0.0001</b>
<i>Dichotomized Olfactory Composite</i>	28 (40.58%)	4 (7.84%)	<b>&lt;0.0001</b>	127 (48.29%)	9 (9.68%)	<b>&lt;0.0001</b>
Hippocampus	34 (49.28%)	11 (21.57%)	<b>0.0019</b>	117 (44.49%)	3 (3.23%)	<b>&lt;0.0001</b>
Corpus Callosum	10 (14.49%)	0 (0.00%)	<b>0.0045</b>	26 (9.89%)	0 (0.00%)	<b>0.0016</b>
Choroid Plexus	30 (43.48%)	3 (5.88%)	<b>&lt;0.0001</b>	108 (41.06%)	8 (8.60%)	<b>&lt;0.0001</b>
Brainstem	10 (14.49%)	0 (0.00%)	<b>0.0045</b>	25 (9.51%)	0 (0.00%)	<b>0.0020</b>
BDS Abnormalities (Categorical)	<b>Mean (Standard Error)</b>		<b>p-value</b>	<b>Mean (Standard Error)</b>		<b>p-value</b>
Supratentorial Extra-Axial Fluid*	0.9839 (0.0989)	0.6000 (0.1069)	<b>0.0075</b>	0.8071 (0.0495)	0.3516 (0.0527)	<b>&lt;0.0001</b>
<i>Cerebellar Composite</i>	0.6812 (0.1121)	0.0980 (0.0578)	<b>&lt;0.0001</b>	0.4791 (0.0536)	0.0000 (0.0000)	<b>&lt;0.0001</b>
<i>Olfactory Composite</i>	1.6912 (0.2693)	0.1961 (0.1011)	<b>&lt;0.0001</b>	2.0229 (0.1452)	0.2418 (0.0817)	<b>&lt;0.0001</b>
<i>Subcortical BDS Composite</i>	4.3188 (0.4043)	1.1569 (0.2046)	<b>&lt;0.0001</b>	4.1141 (0.2210)	0.6989 (0.1268)	<b>&lt;0.0001</b>

**Table 2A: Correlation of Brain Dysplasia Score (BDS) with Demographic Factors (Entire cohort:Univariate Analysis)**

Dependent	Independent	N-used	R-Square	p-value	estimate
<b>BDS</b>	Sex	490	0.000026	0.9096	-0.0359
<b>BDS</b>	GA	487	0.003619	0.1851	0.058461
<b>BDS</b>	PCA	489	0.001664	0.368	0.011933

**Table 2B: Correlation of Brain Dysplasia Score (BDS) with Demographic Factors (CHD cohort, Univariate Analysis)**

Dependent	Independent	N-used	R-Square	p-value	estimate
<b>BDS</b>	Sex	344	0.008447	0.0887	0.680037
<b>BDS</b>	Genetic Abnormality	252	0.045926	<b>0.0006</b>	-1.66277
<b>BDS</b>	GA	341	0.00002	0.9352	-0.00562
<b>BDS</b>	PCA	343	0.002649	0.3419	0.017322
<b>BDS</b>	Birth Weight	248	0.000337	0.7737	-9.1E-05
<b>BDS</b>	Pre/Post operative status	343	0.000662	0.6349	-0.18132
<b>BDS</b>	Term/Preterm	343	0.000651	0.6378	-0.23214

**Table 2C: Correlation of Brain Dysplasia Score (BDS) with Demographic Factors in (CHD cohort, Multivariate Analysis)**

Dependent	N-used	R-Square	Independent		Term/Preterm		Pre/Post	
			p-value	estimate	p-value	estimate	p-value	estimate
<b>Sex</b>	343	0.009957	0.0854	0.6942	0.7409	-0.1633	0.5872	-0.2074
<b>Genetic Abnormality</b>	252	0.048769	<b>0.0006</b>	-1.6806	0.3971	-0.4741	0.8911	-0.0617
<b>GA</b>	341	0.002196	0.6323	0.059	0.5401	-0.5386	0.5487	-0.2303
<b>PCA</b>	343	0.003471	0.3867	0.0168	0.6152	-0.2489	0.8939	-0.0543
<b>Birth Weight</b>	248	0.027317	0.4891	0.0002	0.0368	-1.4958	0.0878	-0.7169





**Table 3: Correlation of Brain Dysplasia Score, Brain Injury and Cortical Maturation Score (TMS)**

	N-used	model p	R-Square	Main Independent Factor		PCA	
				p-value	estimate	p-value	estimate
<b>Hemorrhage</b>	340	0.9876	0.000001	0.9876	0.010146	—	—
<b>Infarction</b>	341	0.604	0.000794	0.604	0.345161	—	—
<b>Hypoxic ischemic injury</b>	328	0.6111	0.000794	0.6111	-0.55119	—	—
<b>Punctate white matter lesion</b>	342	0.8922	0.000054	0.8922	0.071424	—	—
<b>Any brain injury, dichotomized</b>	344	0.5548	0.001021	0.5548	0.243539	—	—
<b>Brain injury composite score</b>	344	0.9042	0.000042	0.9042	-0.03758	—	—
<b>Maturation, Cortical Fold</b>	332	<b>0.0016</b>	0.029645	0.0016	-0.7302	—	—
<b>Maturation, Frontal Cortex</b>	332	<b>&lt;0.0001</b>	0.061511	<b>&lt;0.0001</b>	-0.80238	—	—
<b>Maturation, Insular Cortex</b>	332	<b>&lt;0.0001</b>	0.067464	<b>&lt;0.0001</b>	-1.01932	—	—
<b>Maturation, Cortical Fold &amp; PCA</b>	331	<b>0.0044</b>	0.032554	0.001	-0.78513	0.3255	0.02414
<b>Maturation, Frontal Cortex &amp; PCA</b>	331	<b>&lt;0.0001</b>	0.067676	<b>&lt;0.0001</b>	-0.86858	0.1531	0.034607
<b>Maturation, Insular Cortex &amp; PCA</b>	331	<b>&lt;0.0001</b>	0.07442	<b>&lt;0.0001</b>	-1.10484	0.146	0.035021

**Table 4: Association Between Brain Dysplasia Score and Term Infant Regional Brain Volumes by CHD Status**

Normalized Volumes ( <i>n</i> = 105)	Correlation with BDS (term CHD and term control cohort combined)	Comparison between term CHD and term control cohorts
	<b>p-value (correlation)</b>	<b>p-value (direction)</b>
Right Hippocampus	0.0749 ( <i>N.S.</i> )	0.1476 ( <i>N.S.</i> )
Left Hippocampus	0.1329 ( <i>N.S.</i> )	0.3784 ( <i>N.S.</i> )
Right Cerebellum	0.0535 ( <i>N.S.</i> )	0.1476 ( <i>N.S.</i> )
Left Cerebellum	<b>0.0433 (-)</b>	0.1887 ( <i>N.S.</i> )
Cerebellum	<b>0.0299 (-)</b>	<b>0.0087 (CHD &gt; CON)</b>
Cerebrospinal Fluid (CSF)	0.0517 ( <i>N.S.</i> )	<b>0.0026 (CHD &gt; CON)</b>
Infratentorial CSF	0.2259 ( <i>N.S.</i> )	0.9300 ( <i>N.S.</i> )
Intraventricular CSF	<b>&lt;0.0001 (+)</b>	0.7398 ( <i>N.S.</i> )
Supratentorial CSF	<b>0.0008 (+)</b>	0.3535 ( <i>N.S.</i> )
Deep Grey Matter	<b>0.0138 (-)</b>	0.4877 ( <i>N.S.</i> )
White Matter	0.4550 ( <i>N.S.</i> )	0.6066 ( <i>N.S.</i> )
Cerebral Cortex	0.1687 ( <i>N.S.</i> )	<b>0.0016 (CHD &gt; CON)</b>
Brainstem	<b>0.0391 (-)</b>	0.1311 ( <i>N.S.</i> )

**Table 5: Correlation between Brain Dysplasia Score and Clinical Feeding Outcomes**

<b>BDS Abnormalities (Clinical Outcome Correlates)</b>	<b>Lack of PO Feeds Prior to Discharge p-value</b>	<b>Length of Hospitalization p-value</b>
<b>Hippocampus</b>	<b>0.0025</b>	<b>0.0090</b>
<b>Right / Left Olfactory Bulbs</b>	<b>0.0090 / 0.0050</b>	<b>0.0400 / 0.0300</b>
<b>Right / Left Olfactory Sulci</b>	<b>0.0070 / 0.0070</b>	<b>0.0700 / 0.0700</b>
<b>Extra-Axial Fluid</b>	<b>0.0030</b>	<b>&lt;0.0001</b>
<b>Bilateral Cerebellar Hemispheres</b>	<b>0.0037</b>	<b>&lt;0.0001</b>
<b>Cerebellar Vermis</b>	<b>0.0001</b>	<b>0.0002</b>
<b>Brainstem</b>	<b>&lt;0.0001</b>	<b>N.S.</b>
<b>Corpus Callosum</b>	<b>0.0010</b>	<b>0.0100</b>
<b>Choroid Plexus</b>	<b>0.0100</b>	<b>0.0020</b>
<b>Total Composite</b>	<b>0.0001</b>	<b>0.0020</b>

**Table 6 : Correlation between Brain Dysplasia Score and 15-18 Month Neurodevelopmental Outcomes**

Neurodevelopmental Outcomes (n=90) (Total BDS Correlates)	Non-Parametric			Parametric
	Wilcoxon Mann-Whitney p-value (normal approx.)	Wilcoxon Mann-Whitney p-value (T approx.)	Kruskal- Wallis p-value ( $\chi^2$ )	T-Test p-value
Expressive Language Below Mean	<b>0.0160</b>	<b>0.0190</b>	<b>0.0160</b>	<b>0.0047</b>
Language Composite Below Mean	0.2810	0.2840	0.2790	0.2837
Language Delay	<b>0.0380</b>	<b>0.0420</b>	<b>0.0370</b>	<b>0.0181</b>
Developmental Delay (delayed in $\geq 1$ domains)	<b>0.0280</b>	<b>0.0303</b>	<b>0.0272</b>	<b>0.0284</b>
Global Developmental Delay (delayed in $\geq 2$ domains)	0.1070	0.1110	0.1060	0.1005

**Table 7: Incidence of Brain Dysplasia Score and Subcomponents between Ohia and Wild type Mouse Mutants**

Structure	Ohia Average	Wild Type Average	P value †
<b>BDS Total</b>	<b>4.42</b>	0	<b>&lt;0.001</b>
<b>Cerebellar Fissures</b>	<b>1.5</b>	4.4	<b>&lt;0.001</b>
	Ohia Incidence	Wild Type Incidence	P value *
<b>BDS Dichotomized</b>	<b>55/69, (79.71%)</b>	0/10, (0.00%)	<b>&lt;0.001</b>
<b>BDS Hippocampus or Cerebellum</b>	<b>58/69, (84.06%)</b>	0/10, (0.00%)	<b>&lt;0.001</b>
<b>Aplastic Hippocampus</b>	8/69, (11.59%)	0/10, (0.00%)	0.384
<b>Hypoplastic Hippocampus</b>	14/68, (20.59%)	0/10, (0.00%)	0.223
<b>Dysplastic Hippocampus</b>	<b>44/68, (64.71%)</b>	0/10, (0.00%)	<b>0.002</b>
<b>Combination Hippocampus</b>	22/69, (31.88%)	0/10, (0.00%)	0.133
<b>Hypoplastic Cerebrum</b>	13/68, (19.12%)	0/10, (0.00%)	0.244
<b>Dysplastic Cerebrum</b>	<b>43/68, (63.24%)</b>	0/10, (0.00%)	<b>0.003</b>
<b>Aplastic Cerebellum</b>	2/69, (02.90%)	0/10, (0.00%)	0.678
<b>Hypoplastic Cerebellum</b>	9/67, (13.43%)	0/10, (0.00%)	0.345
<b>Dysplastic Cerebellum</b>	<b>49/67, (73.13%)</b>	0/10, (0.00%)	<b>&lt;0.001</b>
<b>Combination Cerebellum</b>	11/69, (15.94%)	0/10, (0.00%)	0.325
<b>Aplastic Left Olfactory Bulb</b>	<b>33/69, (47.83%)</b>	0/10, (0.00%)	<b>0.024</b>
<b>Aplastic Right Olfactory Bulb</b>	<b>34/69, (49.28%)</b>	0/10, (0.00%)	<b>0.02</b>
<b>Hypoplastic Left Olfactory Bulb</b>	9/67, (13.43%)	0/10, (0.00%)	0.345
<b>Hypoplastic Right Olfactory Bulb</b>	7/65, (10.77%)	0/10, (0.00%)	0.404
<b>Dysplastic Left Olfactory Bulb</b>	2/67, (2.99%)	0/10, (0.00%)	0.673
<b>Dysplastic Right Olfactory Bulb</b>	0/65, (00.00%)	0/10, (0.00%)	—
<b>Combination Left Olfactory Bulb</b>	<b>42/69, (60.87%)</b>	0/10, (0.00%)	<b>0.006</b>
<b>Combination Right Olfactory Bulb</b>	<b>41/69, (59.42%)</b>	0/10, (0.00%)	<b>0.007</b>
<b>Hypoplastic Brainstem</b>	0/66, (00.00%)	0/10, (0.00%)	—
<b>Dysplastic Brainstem</b>	20/67, (29.85%)	0/10, (0.00%)	0.12
<b>Hypoplastic Midbrain</b>	0/67, (00.00%)	0/10, (0.00%)	—
<b>Dysplastic Midbrain</b>	18/67, (26.87%)	0/10, (0.00%)	0.148

† Student's T-test was used to compare Cerebellar Fissure count and BDS Total Score. \* Chi-square analysis was used to compare individual structures as well as BDS Dichotomized and BDS Hippocampus or Cerebellum.



**Table 8: Relationship between Brain Dysplasia Scores/Cerebellar Fissures and Cardiac Lesion Subtypes in Ohia CHD/HLHS Preclinical Groups**

	CHD vs. No CHD			Single vs. Biventricular Morphology			Conotruncal vs. Non Conotruncal			Cyanotic vs. Acyanotic			Arch Obstruction vs. No Obstruction		
	CHD	No CHD	P value *	Single	Double	P value *	Conotruncal	Non Conotruncal	P value *	Cyanotic	Acyanotic	P value *	Obstruction	No Obstruction	P value *
Cerebellar Fissures	1.17 ± 1.55	3.14 ± 1.67	<0.001	1.50 ± 2.12	1.16 ± 1.55	0.86	1.13 ± 1.92	1.22 ± 1.36	0.88	1.16 ± 1.80	1.19 ± 1.39	0.96	0.81 ± 0.98	1.48 ± 1.87	0.13
BDS Total	5.43 ± 2.22	2.73 ± 2.46	<0.001	7.00 ± 2.00	5.32 ± 2.20	0.21	5.27 ± 2.12	5.33 ± 2.46	0.93	5.63 ± 2.34	5.29 ± 2.17	0.61	5.87 ± 1.69	5.00 ± 2.60	0.13

\* Student T-test used to calculate difference between population values within cerebellar fissures and Total Brain Dysmaturation Score (BDS).

**Table 9: Relationship of Genotype to Incidence of Subcortical Abnormalities used to Derive BDS score in CHD/HLHS Preclinical Groups**

Group	A <sup>†</sup>	B <sup>‡</sup>	C <sup>§</sup>	D <sup>  </sup>	E <sup>¶</sup>	F <sup>#</sup>
<b>N Total</b>	24	8	7	4	0	20
<b>Olfactory bulb abnormality</b>	18 (75%)	6 (75%)	6 (85.7%)	4 (100%)	0	9 (45%)
<b>Cerebellar abnormality</b>	21 (87.5%)	7 (87.5%)	7 (100%)	4 (100%)	0	13 (65%)
<b>Hippocampus abnormality</b>	21 (87.5%)	7 (87.5%)	6 (85.7%)	4 (100%)	0	13 (65%)
<b>Brainstem abnormality</b>	10 (42%)	2 (25%)	0 (0%)	2 (50%)	0	6 (30%)

†Group A: N 24, Genotype: Pcdha9(m/m) Sap130(m/m)

‡ Group B: N 8, Genotype: Pcdha9(m/+) Sap130(m/m)

§ Group C: N 7, Genotype: Pcdha9(+/+) Sap130(m/m)

|| Group D: N 4, Genotype: Pcdha9(m/m) Sap130(m/+)

¶ Group E: N 0, Genotype: Pcdha9(m/m) Sap130(+/+)

# Group F: N 27, Genotype: Pcdha9(m/+) or (+/+) Sap130(m/+) or (+/+)

**Table 10: Relationship of Genotype to BDS Score in CHD/HLHS Preclinical Groups**

Structure	ABC** vs. WT <sup>‡‡</sup>			ABC** vs. F <sup>#</sup>			AB <sup>††</sup> vs. F <sup>#</sup>			A <sup>†</sup> vs. C <sup>§</sup>			B <sup>‡</sup> vs. D <sup>  </sup>		
	ABC Median	WT Median	P value*	ABC Median	F Median	P value *	AB Median	F Median	P value *	A Median	C Median	P value *	B Median	D Median	P value *
<b>BDS Hippocampus or Cerebellum</b>	1	0	<b>&lt;0.001</b>	1	1	<b>0.008</b>	1	1	<b>0.021</b>	1	1	0.583	1	1	0.46
<b>BDS Total</b>	6	0	<b>&lt;0.001</b>	6	5.5	0.227	6	5.5	0.251	6	5	0.56	6	6.5	0.558

\* Non-parametric Mann–Whitney U test used to analyze differences in continuous Brain Dysmaturation Score.

† Group A: N 24, Genotype: Pcdha9(m/m) Sap130(m/m)

‡ Group B: N 8, Genotype: Pcdha9(m/+) Sap130(m/m)

§ Group C: N 7, Genotype: Pcdha9(+/+) Sap130(m/m)

|| Group D: N 4, Genotype: Pcdha9(m/m) Sap130(m/+)

¶ Group E: N 0, Genotype: Pcdha9(m/m) Sap130(+/+)

# Group F: N 27, Genotype: Pcdha9(m/+) or (+/+) Sap130(m/+) or (+/+)

\*\* Group ABC: N 39, Genotype: Sap130(m/m), Pcdha9 (\*/\*)

†† Group AB: N 32, Genotype: Sap130(m/m), Pcdha9 (m/\*)

‡‡ Group WT: N 10